Immunology | Review

Energy Dynamics in the Autoimmune Disorders: The Unity of Immunity

K. E. Thorp[1]*, James A. Thorp[2], Christiane Northrup[3], Sue E. Peters[4], Elise M. Thorp[5], Henry L. Ealy[6], Joseph Cleaver[7], Dan McDyer[8], Ronald J. Gourley[9]

[1]MD, Department of Radiology, Sparrow Health System, Lansing, MI.
[2]Chief of Maternal & Prenatal Medicine, ObGyn and Maternal Fetal Medicine, The Wellness Company, FL.
[3]MD, Former Assistant Professor Obstetrics and Gynecology, Vermont College of Medicine, Maine Medical Center, Yarmouth, ME 04096.
[4]PhD, Research Fellow, Children's Health Defense, Franklin Lakes, NJ.
[5]BS FNTP. Williamston, MI.
[6]ND, Energetic Health Institute. email- Info@EnergeticHealthInstitute.org
[7]MD, Regenerative Medicine, Dallas, TX. Email- Info@pwmgmed.com
[8]MD, Private Practice, Ob/Gyn, Jacksonville, FL. email- danmcdyer@bellsouth.net
[9]BS, Founder, CEO, President, TrendTek Bio Inc. Member of Board of Directors BA. email- ron.gourley@trendtekbio.com

INTRODUCTION

The autoimmune disorders, the last major class of disease to be recognized by medical science, present us with a paradox concerning the immune system: originally conceived as a barrier against pathogenic microorganisms that would breach the body's external boundaries, one is led to question why, inexplicably, it should suddenly turn against the body and attack its own tissues? The notion was so counterintuitive that early 20th century immune researcher Paul Ehrlich advanced the doctrine of horror autotoxicus, arguing that such a possibility would be utterly 'dysteliologic' [1-3].

And yet evidence in support of autoimmunity was present from the beginning. By the early years of the 20th century, it was known that immune reactions could be damaging rather than protective: in 1902 Richet reported on anaphylaxis; in 1906 von Pirquet described allergy and immune-complex disease. Perhaps such reactions seemed more palatable to turn-of-the-century scientists as they were directed against environmental substances. Autoimmunity, however, remained a conceptual bête noire until mid-century.

406

The paradox dissolves once one recognizes that it originated largely in how scientists expected the immune system should behave. Early in the formation of their science they seized upon certain notions, like the nature of inflammation or the primacy of the antibody response, that rather soon became accepted as fact. In the century that followed a stream of reports challenged these orthodox conceptions and begged for a fundamental reappraisal of ideas but this never happened. The recent SARS-CoV-2 pandemic exposed grave flaws in 20th century immune theory that must now be rectified.

Equally, it raises concerns about experimental science itself and the inability of researchers to reexamine their assumptions and make in-course corrections. Reflexivity has never been a defining attribute of the science community. Instead, scientists have been subject to speculative (and reactive) thought formation as well as to the sway of opinion leaders who, by and large, have steered its development. From the onset science possessed all the characteristics of other mass movements that came to define the 20th century.

As in other mass phenomena scientists were collectively swayed by a sense of awe over its potential to amass power and effect change. Peter Medawar, one of the architects of 20th century immune theory and co-recipient of the 1960 Nobel Prize wrote: 'In terms of the fulfillment of declared intentions, science is incomparably the most successful enterprise humans have ever engaged upon. Visit and land on the moon? A fait accompli. Abolish smallpox? A pleasure . . .' [4] (Figure 1). Scientists' confidence in their venture has never waned even an iota.

Figure 1: Immunologist Peter Medawar, discoverer of immune tolerance, co-recipient of the 1960 Nobel Prize, claimed that the basis of the immune response centered around the ability of the immune system to distinguish between self and non-self.

(From: https://quotesgram.com/peter-medawar-quotes/)

Early 17th century scientists coined the maxim *Plus Ultra*, meaning 'further beyond', implying no limit to the advance of scientific knowledge or the power science would accrue. Three-and-a-half centuries later Medawar echoed the same sentiment: 'Never once in the history of science have we reached a *Non Ultra*', i.e., a point beyond which no further progress is possible, 'nothing can impede or halt the advancement of scientific learning . . .'. Science became destiny.

But it would seem that scientists have met their match in the surging epidemic of chronic disease: autoimmune disorders, chronic heart failure, chronic kidney disease, neurodegenerative disease, epilepsy, diabetes, the metabolic syndrome, and a host of cancers now spread unchecked across the globe and are largely refractory to their treatments. Heroic science-based physicians can perform life-saving organ transplants but can't cure a simple case of asthma. Something is amiss.

In the 1980s evidence surfaced in the medical literature overturning the accepted model of cardiac function that had dominated 20th century medical thought. This was but the first of other dominoes that would fall. Emerging evidence now points to the presence of an organized energy field originating in the blood through the contraction and dilation cycles of the heart that organizes all bodily functions [5, 6].

This blood-borne energy field was described in detail by 2nd century Roman physician Galen and was accepted as fact by physicians for over 1500 years until it was arbitrarily discarded by chemically-oriented physicians in the 17th and 18th centuries [7]. Central to Galen's humoral system of medicine was the doctrine of *omnia incipit in sanguine,* everything begins in the blood. Based on this notion all bodily inflammation was regarded as an indication of deficient energy generation in the blood.

In this paper we examine the autoimmune disorders (AIDs) not from a cellular/ molecular standpoint as scientists have attempted for decades but from a dynamic energy-based perspective. Not only does this framework account for the origins of these disorders but it explains phenomena that cell-based mechanisms cannot. In addition, we examine the historical basis of 20th century immune theory and point to serious errors in the research literature that have lain unrecognized for over a century and which led to broad misconception of immune functions.

THE MANY FACES OF INFLAMMATION

The AIDs represent a clinically diverse group of conditions said to arise from 'dysregulation' of the immune system leading to inappropriate activation of lymphocyte and macrophage cells, production of auto-antibodies (auto-Abs), and increased levels of pro-inflammatory cytokines like tumor necrosis factor-α, interferon-γ, interleukin (IL)-1, IL-2, IL-6, IL-17 and others in affected tissues and the blood. Scientists claim such dysregulated immune activity results from a loss of 'self-tolerance', i.e., inability of immune cells to distinguish between self and non-self, which they ascribed to genetic mutations [8, 9].

Over 80 self-directed inflammatory syndromes have been described ranging from relatively common conditions like type I diabetes, thyroiditis and rheumatoid arthritis to rare disorders like Guillain-Barre syndrome, myasthenia gravis or scleroderma [10]. They may affect single organs as in the case of multiple sclerosis, thyroiditis or diabetes, or manifest systemically and involve multiple organs as with systemic lupus erythematosus (SLE) or vasculitis. A single entity like diabetes can cluster in multiple family members while multiple AIDs can affect the same individual. In recent years so-called overlap syndromes have been described in which distinct entities like rheumatoid arthritis and

SLE, called 'rhupus,' coexist in the same individual [11-16]. The AIDs defy simple classification [17].

In the liver inflammation may affect hepatocytes to manifest as hepatitis or involve bile ducts and present as primary biliary cirrhosis. In the skeletal system it may present as rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis. Psoriasis, on the other hand, characterized by chronic, recurrent skin lesions, may coexist with arthritis, inflammation of ligaments and tendons, or uveitis [18]. Crohn's disease, with origins in the bowel, frequently coexists with extra-intestinal disease involving the skin, joints or eyes [19, 20]. Given the striking overlap of symptoms, distinguishing among the different AIDs is challenging and diagnosis often prolonged and costly. And despite recent advances in treatment only a minority of affected individuals experience sustained remission.

The AIDs occur at any age although each subtype has a typical age of onset. Most AIDs disproportionately affect women with some, like SLE, having prevalence ratios as high as 10-15:1 [21, 22]. Current opinion suggests that AID represents a complex interplay between genetic and environmental factors. Genome-wide association studies have implicated hundreds of genes in the various AIDs but none have significant predictive value. The concurrence of AID in identical twins is only 12-67% indicating that factors other than heredity are in play.

A plethora of environmental influences have been identified including diet, gut microbiota, infection, smoking, hormones, as well as geographical influences such as latitude and sunlight exposure [23, 24]. Included in this list are some of the very medicines used to treat the AIDs as well as vaccines [25-27]. While some of these factors play a permissive role, others such as sunlight exposure and infection are more directly involved.

The complex relation between infection and autoimmunity highlights the pivotal role inflammation plays in both disorders [28]. Bacterial infections can trigger self-directed inflammatory reactions that can be short-lived or become chronic and resemble the autoimmune state. Reactive arthritis, formerly known as Reiter's syndrome, may occur following infections in the genitourinary or digestive systems and present as inflammatory arthritis, uveitis, and skin lesions resembling those of psoriasis [29-32]. Behçet's disease is a systemic vasculitis characterized by recurrent ulcers in the mouth and genital regions, skin lesions and uveitis. The cause of Behçet's disease remains unknown but evidence points to an infectious etiology [33-35].

More striking is the relation between the AIDs and viral illness. For decades it has been recognized that viral infections can trigger AIDs like SLE, rheumatoid arthritis, multiple sclerosis, vasculitis, and more [36-39]. Offending viruses include herpes, Coxsackie B, hepatitis B & C, cytomegalovirus, parvovirus and the whole gamut. Mechanisms are poorly understood but ascribed to 'molecular mimicry', i.e., cross-reactivity based on similarities in protein structure between viral antigens and that of the body which, in turn, is said to activate lymphocytic T-cells and the inflammatory cascade. But this says nothing about why such events should occur in some cases and not in others.

The SARS-CoV-2 pandemic revealed striking similarities between COVID-19 infection and the AIDs on multiple levels: overlap of clinical symptomatology; nearly identical inflammatory response patterns, particularly cytokine profile and appearance of auto-Abs; and worsening of pre-existing AIDs or appearance of new AID syndromes after COVID-19 infection.

While fever, respiratory symptoms and sore throat are primary manifestations of COVID-19, frequent

ancillary phenomena include muscle [40-42] and joint [43-45] pain as well as skin rashes [46-48] which also affect various AIDs. Widespread endothelial inflammation is the primary pathogenic mechanism underlying COVID-19 infection and vasculitis of small, medium and large arteries is ubiquitous [49-56]. Endothelitis, as we show in earlier writings, is a direct consequence of decreased energy generation in the blood [57, 58]. In most cases acute-phase phenomena are transitory and disappear with resolution of the illness.

Excessive release of pro-inflammatory cytokines, aka the cytokine storm, was originally believed to be a characteristic feature of the AIDS but in recent decades has been linked to a variety of infectious and non-infectious conditions. It is now regarded to be a generic accompaniment of inflammation *per se* [59-63]. The cytokine storm is common in COVID-19 syndrome and correlates with disease severity. In severe cases the hyperinflammatory state induced by the cytokine storm drives subsequent respiratory distress syndrome, multi-organ failure and coagulopathy, all of which reflect progressive deterioration of blood energy generation.

Early on the presence of auto-Abs in the blood was regarded as pathognomonic for the AIDs but this too has been refuted by a flood of contradictory evidence [64-68]. Numerous studies document the presence of auto-Abs in COVID-19 infection and the number increases in proportion to the severity of infection. Up to a dozen different auto-Ab varieties have been detected some individuals. Anti-nuclear antibodies were found in up to 35% of affected persons; anti-Ro/SSA in 25%; anti-rheumatoid factor in 19% [69]. Such auto-Abs are present in the blood of individuals with SLE and rheumatoid arthritis.

The most compelling evidence for the conjoined nature of the AIDs and COVID-19 is found in a spate of reports documenting worsening of pre-existing AID or triggering of new AID after COVID-19 infection or vaccination including: SLE [70-74], rheumatoid and other inflammatory arthritidites [75-86], inflammatory myositis [87-95], myocarditis [96-99], vasculitic syndromes like Kawasaki's disease [100-104], type I diabetes [105-110], multiple sclerosis [111-117], autoimmune encephalitis [118-120], Guillain-Barré syndrome [121-125], autoimmune thyroid disease [126-129], autoimmune hepatitis [130-134], autoimmune hemolytic anemia [135-139], autoimmune dermal conditions [140-144], scleroderma [145-148], and sarcoidosis [149-154]. Either we regard these events as random and coincidental or we must accept the primacy of inflammation in both forms of disease. Similar adverse effects are observed with therapies scientists employ to treat the AIDs.

In recent decades so-called 'biologic' agents have become popular treatments for various AIDs [155-156]. There are up to a dozen monoclonal Ab preparations that target one or another aspect of the 'dysregulated' immune response – either interleukins, interferons, tumor necrosis factor, or B- & T- lymphocytes – and thereby mitigate (but not eliminate) the inflammatory response. Aside from their inconvenience (they must be given intravenously) and prohibitive cost ($10,000-$30,000 per year) they induce a range of inflammatory effects similar to what we just saw in viral illnesses [157].

In addition to injection site reactions [158], acute hypersensitivity and immune-complex phenomena [159-161], as well as predisposition to infectious complications like tuberculosis [162], auto-Ab formation and AIDS are not infrequent. Clinical symptoms include skin rashes, arthritis, muscle pain, oral ulcers, and photosensitivity [163-166]. Various studies report anti-nuclear Abs in 40-

100% of cases, anti-DNA auto-Abs in 11-62%, and antiphospholipid auto-Abs in 2-12% [166-169]. Autoimmune syndromes include multiple sclerosis, optic neuropathy, uveitis, psoriasis, vasculitis, inflammatory bowel disease, and inflammatory myositis [170-193]. Another not uncommon occurrence, 'paradoxical inflammation', presents as exacerbation of the very condition for which the treatment is intended and, often, appearance of psoriasis-like areas of inflammation involving the skin [194-198].

To assert that AIDs have any kind of distinct and independent existence is an absurdity. They are instead variable, amorphous entities that come and go based on ambient conditions in the blood. The only plausible explanation for autoimmune inflammatory phenomena seen in relation to viral illnesses or treatment with biological agents is that inflammation *per se* is the primary driver of such events and must itself be secondary to some prior and more fundamental cause, which we have ascribed to a deficiency in the blood-borne energy field. We examine the energetic aspect in greater detail.

CARDIOVASCULAR DYNAMICS

In recent years another unexpected link between the AIDs has emerged: a shared predisposition for cardiovascular disease. Cardiac manifestations are the leading cause of morbidity and mortality in SLE; affected women are said to have a 7-8-fold increased risk of developing coronary artery disease compared with other women [199, 200]. Cardiovascular disease in rheumatoid arthritis occurs up to a decade earlier than in the general population and individuals are twice as likely to develop heart disease [201, 202]. One study found evidence of myocardial ischemia in rheumatoid arthritis patients at a rate comparable to that seen in diabetics [203]. But the trail of evidence doesn't end there.

Similar adverse scenarios have been documented in most of the common AIDs including multiple sclerosis, scleroderma, type 1 diabetes, psoriatic arthritis, ankylosing spondylitis, Sjögren's syndrome, dermatomyositis, polymyositis and others [204]. Despite all emerging treatment options individuals with AIDs have reduced life expectancy in large part due to cardiovascular causes which include myocardial ischemia, inflammation and fibrosis, conduction and rhythmic disturbances, heart failure, and valvular disease. In most cases cardiac abnormalities are present years before individuals develop symptoms. What is happening here?

Scientists are at a loss to explain this excess cardiovascular risk. Some ascribe it to systemic inflammation induced by the cytokine storm and spillage of reactive oxygen species into the vascular system related to impaired cell metabolism. Others point to widespread endothelial dysfunction associated with various AIDs. The answer is both of the above: defective energy generation in the blood directly impairs endothelial function and cell metabolism. This compels us to reexamine conventional ideas about cardiac function.

For most of the 20th century medical scientists regarded systole as the primary phase of the cardiac cycle. Such notions were originally advanced by William Harvey in *Anatomical Studies on the Motion of the Heart and Blood* (1628): 'the heart does not act in diastole but in systole for only when it contracts is it active,' and later, 'likewise, it is not true, as commonly believed that the heart by its own action or distention draws blood into the ventricles' [205]. Harvey rejected a line of medical thought that went back nearly 1500 years to Galen who argued for the primacy of diastole and its energetic origins [206].

In the 1980s reports described negative intraventricular pressures in the early diastolic

phase of the heart cycle which, researchers soon realized, must account for the forward movement of blood and diastolic filling [207, 208]. A 1986 article in *Scientific American* entitled 'The Heart as a Suction Pump' proposed a new diastolic-centered model of cardiac function [209]. In the mid-1990s another paper refuted Harvey's propulsion theory of heart function [210]. Numerous studies describe spiral arterial flow currents which can only be explained on the basis of a suctional force which itself can only be explained on an energetic basis [211-224].

For over a century, cardiologists have claimed systolic contraction is induced by nerves that course over the outer surface of the heart but is this correct? In animal experiments Galen observed that when the heart was cut out and placed in a fluid bath it continued to dilate and contract, a phenomenon known as cardiac automaticity. By the same token, transplanted hearts continue to function in recipients even though nerve conduction has been interrupted. Could cardiac nerves serve another purpose?

What happens during systolic contraction of the ventricle is similar to that which happens during induction of an external magnetic field by electrification of ferrous objects. As the ventricle contracts, iron in the myocardium and blood is brought into closer apposition while nuclei align and precess synchronously on the basis of field interactions. Electrical potentials in the nerves saturate the field and induce transient formation of a 3D magnetic field in the heart wall and ventricular chamber which forms the energetic basis of diastole. Expansion is brought about by conformational change in blood and heart proteins [225-227].

By the late 1980s numerous studies had affirmed the primacy of diastole in the cardiac cycle and, moreover, found that impaired outward movement of the ventricular and arterial walls, aka 'diastolic dysfunction', was the defining feature of a wide range of chronic conditions including the AIDs, hypertension, diabetes, obesity, depression, cancers, as well as organ failure syndromes like chronic heart failure and chronic kidney disease [228, 229]. This is to say these conditions all share common energetic origins. The spiral of deterioration begins with a single ubiquitous phenomenon known as microvascular dysfunction.

In the 1970s cardiologists noticed increasing numbers of people who complained of typical angina-like chest pain and who, on exercise stress-testing, developed ECG abnormalities consistent with myocardial ischemia but, surprisingly, were found to have normal appearing coronary arteries by angiography. Named Cardiac Syndrome X, symptoms result from diastolic dysfunction at the microvascular level. Blood inflammatory markers like C-reactive protein are often elevated. A preponderance of those affected are post-menopausal women [230-233]. Originally thought to be benign it is now regarded as a progressive condition linked to poor quality of life and increased mortality.

Microvascular dysfunction is not limited to the heart but, instead, is a body-wide process. Multiple organs, including brain and kidneys, are affected [234-238]. Many with coronary microvascular dysfunction have abnormal brain perfusion and are at higher risk for neurologic problems like stroke. Consistent with its systemic nature, coronary flow reserve can be estimated by measuring waveforms in other vascular territories like the retinal arteries [239].

During periods of increased physical activity or emotionally stressful situations microvascular dysfunction impairs energy flow to the myocardium, aka 'decreased coronary flow reserve', producing scattered areas of muscle ischemia which evoke

anginal symptoms. Impaired microvascular function results in mitochondrial dysfunction in endothelial cells causing inflammation [240-242]. Such 'oxidative stress' in endothelial cells induces the so-called cytokine storm triggering an immune response. Whether involving the heart, kidneys, or brain, microvascular dysfunction sets into motion a spiral of chronic low-grade inflammation which is subsequently made worse by a host of risk factors [243-250]. Coronary microvascular dysfunction is increasingly recognized as a contributor to poor outcomes in the AIDs [251].

Rheumatoid arthritis (RA), the most common AID, with a 3:1 female-to-male pattern of involvement, characterizes the intertwined relation between the AIDs and heart disease. Most individuals with RA die of cardiovascular causes [252-255]. Hypertension is present in 50-70% of subjects [256-260]. Blood inflammatory markers are commonly elevated [261, 262]. Diminished coronary flow reserve, microvascular and diastolic dysfunction are found in significant numbers of people with RA even in the absence of cardiovascular symptoms [263-272]. One study found echocardiographic evidence of ischemia in 67% of RA subjects, over twice that seen in the control group (31%), and nearly that in diabetics (79%) [273]. Such ischemic phenomena lead to fibrosis and remodeling of the myocardial wall. Ventricular dysfunction, both diastolic and systolic, are present in 30-50% of subjects [274-279].

Studies in women with SLE found decreased coronary flow reserve compared with healthy controls. The degree of reduction is proportional to disease activity and duration [280-288]. One study, conducted over 5 years, examined SLE patients with chest pain using MRI and CT angiography and found up to half had microvascular ischemia in the absence of obstructing lesions in large coronary vessels. After 5 years most had persistent chest pain, and nearly half had similar or worsened

myocardial perfusion [289]. Other studies find that a high percentage of Individuals with SLE have subclinical myocardial injury [290].

Systemic sclerosis (scleroderma), which primarily involves connective tissues and has a female-to-male preponderance of up to 8:1, is characterized by skin sores, more common in the fingers and toes, and fibrosis affecting the skin and other organs like the lungs [291-293]. Primary myocardial involvement and blunted coronary flow reserve are common early features [294-299]. One study employing cardiac MRI found at least one cardiac abnormality in 75% of subjects with scleroderma. Other findings included diastolic dysfunction (35%), reduced ejection fraction (23%), and wall motion abnormalities (31%) [300].

Another MRI study in scleroderma patients with no history of heart symptoms found that, on average, 45% *already* had myocardial fibrosis. This increased to 59% in subjects with more diffuse disease. Almost 80% had subendocardial perfusion defects with associated elevated blood inflammatory markers [301]. One can only conclude that fibrosis as well as systolic and diastolic ventricular dysfunction are the result of chronic inflammation induced by microvascular ischemia. Such a connection is seen vividly in the commonly encountered entity known as Raynaud's phenomenon.

Raynaud's phenomenon, seen in multiple AIDs, is a microvascular disorder characterized by episodic vasospasm and ischemia most commonly associated with cold exposure [302, 303]. Raynaud's, a frequent accompaniment of scleroderma, causes digital ischemia that may result in chronic skin ulcers. Cardiac imaging with thallium-201 found simultaneous cold-induced perfusion defects in the heart, even in subjects without cardiac symptoms, highlighting the systemic nature of microvascular dysfunction [304-307]. Along this same line, retinal microvascular abnormalities have been described

in rheumatoid arthritis [308, 309], SLE [310-313], scleroderma [314, 315], multiple sclerosis [316, 317], type 1 diabetes [318-320], inflammatory bowel disease [321, 322], Kawasaki's disease [323], Sjögren's syndrome [324] and autoimmune thyroid disease [325]. As Galen claimed, the heart and arteries function as one.

Since the 1980s heart rate variability (HRV), which assesses the beat-to-beat fluctuations in cardiac rhythm, has been regarded not only as a strong indicator of cardiac health but a leading predictor of all-cause morbidity and mortality [326]. Easily obtainable with standard ECG equipment or wearable devices, the most common methods are known as time- and frequency-domain analyses [327-330]. Decreased HRV has been reported in *every single* chronic disease, including the AIDs. In addition, decreased HRV is seen in many acute conditions including COVID-19 infection and the long-COVID syndrome [331-337].

HRV is said to reflect moment-to-moment changes in autonomic balance, i.e., between sympathetic and parasympathetic pathways, which, furthermore, is said to drive all adaptive cardiac functions. Early in the 20th century Nobel Prize-winning neurophysiologist Charles Sherrington, in his highly influential work *The Integrative Action of the Nervous System* (1906), advanced the concept of the 'dominant brain' claiming that all bodily functions were under the control of the brain [338]. This assumption formed the basis of J. N. Langley's 1903 work on the autonomic nervous system which, in his formulation, consisted of a network of one-way outflow pathways originating in the brain that either increased (sympathetic) and decreased (parasympathetic) heart rate [339]. Such notions are now generally regarded as highly problematic if not outright wrong [340].

Decreased HRV has been reported in rheumatoid arthritis [341-343], SLE [344-346], scleroderma

[347-349], multiple sclerosis [350-352], Guillain-Barré syndrome [353, 354], psoriatic arthritis [355, 356], inflammatory bowel disease [357-359], Sjögren's syndrome [360-362], type 1 diabetes [363-365], Behçet's disease [366, 367], autoimmune thyroid disease [368] and more. But what does decreased HRV actually imply? Studies indicate it is associated with higher average heart rate [369-373] along with stiffening of arteries [374-381] both of which reflect heightened sympathetic activity. In addition, numerous studies document a tight inverse relation between HRV and inflammation: as inflammatory markers increase HRV decreases [382-387]. Decreased HRV is a hallmark of hypertension, obesity, diabetes and the metabolic syndrome all of which are characterized by microvascular dysfunction, increased sympathetic activity and systemic inflammation [388-392].

Researchers claim that imbalance between sympathetic and parasympathetic systems, aka 'cardiac autonomic neuropathy', forms the basis of the AIDs [393-399]. And because HRV studies consistently point to diminished parasympathetic activity they conclude that the vagus nerve in some manner possesses anti-inflammatory properties [400-407]. On this basis they seek strategies to augment parasympathetic activity such as enhancement of cholinergic nerve transmission and implantation of vagal nerve stimulator devices [408-419]. But all of this is premised on the dominant brain model and whether or not the autonomic nervous system actually controls the heart.

In a recent article examining the energetic basis of the neurodegenerative disorders we show that both the brain and peripheral nerves derive current flow through the cerebrospinal fluid and extracellular fluid pathways [420]. Diminished energy generation in the blood impacts current flow through the nervous system. In sudden cardiac arrest there is immediate cessation of all nerve

transmission and brain function indicating the primacy of the heart and cardiovascular system.

Decreased HRV has less to do with autonomic imbalance than decreased energy generation in the blood. The kidneys are the first organ to sense this state of affairs and, through the renin-angiotensin system, induce activation of the sympathetic axis via the adrenals so as to increase energy generation by the heart. This, in turn, diverts current flow from parasympathetic pathways. It is excess sympathetic not decreased parasympathetic activity that best correlates with inflammation and reduced HRV which, in the end, is just another way of assessing microvascular dysfunction. The AIDs are primarily energetic in nature. But this leaves us with a plethora of questions regarding the nature of the immune system that must now be addressed.

RETHINKING IMMUNITY & AUTOIMMUNITY

What we now know as the science of immunology has its origins in the closing decades of the 19th century. It is difficult to separate concepts of immunity that emerged during this era from early biological ideas regarding the nature of species and speciation. By the time immunologists came onto the scene Darwin's theory of evolution thoroughly dominated biological thought and strongly influenced not only the focus of experimental research but how facts would be interpreted.

Darwin had broken rank with ancient ideas concerning the nature of species and regarded them as evolutionarily emergent entities that spontaneously arose among inbreeding groups of organisms, a notion which would seem to engender a chicken and egg conundrum. Without resolution of such incongruities evolution became conceived as the sole driver of progressive speciation; species, in turn, were regarded as distinct and differentiated biological entities which, in the end,

were genetically determined. This is 20th century biology in a nutshell.

As medical historian Pauline Mazumdar recounts in her insightful work *Species and Specificity: An Interpretation of the History of Immunology* [420], there arose two opposing factions in 19th century biology, what others have referred to as 'splitters' and 'lumpers,' those who would explain immune phenomena on the basis of their differences and who saw experimentation as a means of making increasingly fine distinctions, and those who sought to integrate experimental phenomena into an overarching unity. One group saw variation and divergence, the other unity within diversity. These two organic modes of perceiving immune phenomena locked into fierce conflict during the closing decades of the 19th and early decades of the 20th centuries.

German bacteriologist Robert Koch argued forcibly for the distinct identity and autonomy of the various bacterial species. His opinions dominated late-19th century bacteriological thought. Different bacterial species, in turn, produced their characteristic clinical syndromes on the basis of specific attributes. On this logic it only stood to reason that such sicknesses should be treated with specific medicines.

Physician-chemist Paul Ehrlich, arguing that all cellular functions were chemical in nature, advanced the notion of Abs and antigens (Ags). All immune reactions, he claimed, were based on specific molecular interactions in which the two opposing entities joined together in lock-and-key fashion (Figure 2). By the same token Ehrlich, an early proponent of cell receptor theory, argued that specific drugs, what he called 'magic bullets', could combat a host of specific diseases. This forms the basis of virtually all 20th century pharmacological strategies including vaccines.

415

Figure 2: Physician-chemist Paul Ehrlich, co-recipient of the 1908 Nobel Prize, claimed that antigen-antibody interactions formed the basis of the immune response.

(From: https://fineartamerica.com/art/paul+ehrlich)

In the 1880s biologist Elie Metchnikoff observed under the microscope cells of developing starfish larvae wandering about in the tissues. Suspecting they played a role in the breakdown of cellular substances, he introduced a rose thorn into an organism and watched as cells surrounded the foreign object [422-424] (Figure 3). Calling them phagocytes or 'eating cells', Metchnikoff argued that such cells, now called macrophages, formed the basis of the immune response and were part of a more general set of primitive functions, an internal digestive system so to speak, the purpose of which was to mediate the breakdown of molecular and cellular substances (Figure 4).

Figure 3: Zoologist Elie Metchnikoff, discoverer of phagocytosis and phagocytic cells, co-recipient of the 1908 Nobel Prize, argued that such cellular activities formed the cornerstone of the immune response.

(From: https://fineartamerica.com/featured/1-elie-metchnikoff-ilya-ilich-mechnikov-mary-evans-picture-library.html)

Figure 4: Stained histologic preparation of macrophage.

(From: https://openeducationalberta.ca/mlsci/chapter/macrophage/)

It is fact that the main advocates of the two opposing factions, Ehrlich and Metchnikoff, jointly shared the 1908 Nobel Prize – seemingly a nod in each direction – but their fates sharply diverged: the cellular perspective fell into steep decline for almost a half-century as chemists grabbed the reins and sought to define the immune response on a molecular basis, a period immunologist Arthur Silverstein, in his acclaimed work *A History of Immunology*, calls the Dark Age of experimental immunology [425].

This clash of ideas can be seen in terms of a broader historical dialectic. It is said that controversy is the most productive form of scientific discourse. When assumptions are roundly agreed upon, they are more likely to remain unquestioned and unexamined. Disputation forces concepts to be made explicit. Over the course of the 20th century, each opposing perspective would have ample opportunity to state its case and it would be left to later generations to draw necessary conclusions and complete the synthesis.

In 1948 Rose observed agglutination of red blood cells (RBCs) in a woman with rheumatoid arthritis, the first formal recognition of auto-Abs. The auto-Ab, called rheumatoid factor, was later found to

be an IgM Ab directed against IgG Abs [426]. In 1951 Harrington injected sera from subjects with idiopathic thrombocytopenic purpura into healthy volunteers and observed an abrupt decrease in their blood platelet counts [427]. Auto-Abs had reacted with volunteers' platelets and caused their destruction. In the mid-1950s various studies found that serum from subjects with autoimmune thyroiditis had auto-Abs directed against thyroglobulin. Since that time hundreds of auto-Abs capable of reacting against self-tissues have been described in the AIDs. Auto-Abs are now regarded as the hallmark of the AIDs and the gold standard for diagnosis [428, 429].

In the 1960s researchers distinguished between two classes of lymphocytes, so-called thymic-derived T-cells, responsible for cell-mediated defense functions, and B-cells, originating in the bone marrow, involved with Ab production. T- and B-cell responses are antigenically driven and directed toward specific pathogenic sources, whether infectious, toxic, neoplastic, or the AIDs.

Increasingly scientists came to distinguish between 'adaptive' immune responses, involving Ag/Ab and receptor-mediated responses, and 'innate' immune functions subsumed by the phagocytic system [430].

In the late 1950s Australian biologist MacFarlane Burnett, a staunch critic of chemically oriented theories, advanced the first major synthesis of 20th century immunology with his Clonal Selection Theory: all immune activities, including synthesis of molecular mediators, are effected by cellular functions (Figure 5). Burnett jointly shared the 1960 Nobel Prize with Peter Medawar. Thereafter auto-Abs, and thus the AIDs, became conceived as a consequence of mutations in particular cell lines, aka 'forbidden clones', that proliferated and synthesized self-directed Abs. Studies surfacing during the SARS-CoV-2 pandemic call into question the primacy of the Ab response and adaptive immune system as well as the nature of auto-Abs.

Figure 5: Biologist MacFarlane Burnett, co-recipient of the 1960 Nobel Prize, argued for the primacy of the cellular response in the immune reactions. Advanced the Clonal Selection Theory which explains the genetic basis of the adaptive immune response.

(From: https://www.bilgiustam.com/frank-macfarlane-burnet-kimdir/)

During COVID-19 infection, Abs rarely appeared in the blood before 12 days and sometimes not for 21 days. In many cases symptoms resolved before Abs even appeared. Once present in the serum, anti-spike protein IgG Ab levels waned and by 3-5 months were usually negligible [431-440]. By contrast, Ag-specific memory B cell levels often remained unchanged for 6 months or more [441]. Evidence clearly points away from Abs and toward cellular dynamics in the immune response.

Another provocative line of evidence: a significant

portion of COVID-19 infected individuals, as confirmed by PCR testing, never developed an Ab response. Such 'nonseroconverters' ranged from a low of 5% in one study to a high of 36% in another; other studies found rates in the 15-25% range. Nonseroconverters tended to have milder disease, more rapid viral clearance and lower blood inflammatory marker levels [442-447]. Such findings point to the pivotal role of the innate immune response in early infection.

Other studies found that individuals with more severe disease had higher Ab levels than asymptomatic or mildly affected cases [448-464]. Hospitalized patients had Ab levels up to 3000-fold higher than milder cases or during the recovery period [465-468]. Researchers have no satisfying explanation. Another study found obese individuals with the metabolic syndrome, a group which had worse clinical outcomes, also had higher Ab levels [469]. This is to say that mildly affected and asymptomatic individuals, those with the best clinical outcomes, paradoxically had the lowest Ab responses.

Such findings make no sense unless one accepts that Abs have only a supporting role in the immune response. It seems likely that Ab production is a fallback mechanism implemented when innate immunity is deficient. This inconvenient fact overturns Ehrlich's 120 year-old entrenched dogma. By the same token it explains why COVID-19 vaccines, which stimulate Ab production and provide short-term protection, don't confer long-term immunity. Equally damaging to modern immune theory is the auto-Ab phenomenon.

COVID-19-infected subjects had marked increases in auto-Ab levels compared with non-infected individuals. As in the AIDs, an array of auto-Abs directed against cytokines, chemokines, cell surface proteins as well as RNA and DNA appeared during the course of infection. Auto-Abs,

depending on type, were present in 10%-50% of cases. Studies found that auto-Ab levels tracked directly with rising levels of anti-SARS-CoV-2 Abs and with disease severity suggesting they formed spontaneously during the course of the illness [470-480]. What does this mean?

Genetic mechanisms explain neither the appearance of auto-Abs during the acute phase of the illness nor formation of auto-Abs themselves. Genes code for the primary structure of proteins, i.e., the amino acid sequence, but the secondary and tertiary structure, i.e., the 3D conformation of Abs, is determined solely by energy dynamics. Once formed, primary polypeptide chains are surrounded by cell water, called the hydration layer, and interactions between separate chains as well as folding itself are effected on the basis of energy-driven colloidal interactions [481-485].

Numerous early 20th century scientists questioned Ehrlich's notion of lock-and-key specificity. By that time tens of thousands of antigenic substances had been identified and it was argued that there could not possibly be enough genes to code for such a vast number of Abs. Austrian Researcher Karl Landsteiner, discoverer of the ABO blood groups, argued in favor of a much smaller number of Abs with overlapping specificities. Landsteiner has been proven correct on this point. He also argued that electrochemical forces mediate specific affinity. In his electrolysis experiments, charged acidic and alkaline colloids not only moved toward opposite poles but actively precipitated each other [486].

When undergoing conformational change, aka allosterism, proteins reorganize three-dimensionally to form dynamic linkages between often widely separated domains, either on the same chain or between different chains. Such activities are effected by hydrogen bonding and dipole-dipole interactions that originate in the surrounding fluid milieu. Ag/Ab interactions occur

in the same way. Evidence indicates that auto-Abs are simply misfolded proteins whose altered specificity overlaps with the body's own tissues. On this basis one is once again drawn back to blood energy dynamics.

The question thus arises as to the actual role auto-Abs play in the genesis of the AIDs. There has been increasing recognition of the presence of a wide array of auto-Abs in normal, healthy individuals. Called 'natural' auto-Abs they are said to occur in 5-10% of healthy blood donors and up to 50% in selected groups of asymptomatic individuals [486-490]. Some argue they result from forbidden clones due to failure of clonal selection; others regard them as evolutionarily conserved mechanisms that clear 'physiologic debris' from the body. But why would this be necessary when there are phagocytic cells?

In recent decades evidence necessitated formulation of a new class of disorders, the 'autoinflammatory diseases', to accommodate a growing number of chronic conditions like Familial Mediterranean Fever, Still's disease and Behçet's syndrome characterized by episodic inflammation associated with fever, skin rashes, ocular manifestations and arthritis *in the absence of auto-Abs* [491-496]. Such disorders, which are said to have a genetic basis, are now recognized to originate from innate immune dysfunction.

Evidence thus points to one inescapable conclusion: auto-Abs are neither necessary nor sufficient to explain the AIDs. This being the case, where do we look for answers?

SPLEEN & INTERNAL DIGESTION

The spleen was overlooked for much of the 20th century and its functions incompletely understood. As the only major organ that can be removed without immediate dire consequence it was regarded by many as mainly a storage compartment for red and white blood cells. The so-called ductless gland has been a source of speculation throughout history.

Structurally possessing connections only to the vascular system, and beginning its early development as an ingrowth of blood vessels and primitive immune cells, its entire raison d'être seems tied to the blood and vascular system [497, 498]. Plato claimed it kept the blood 'bright and shining'. Aristotle and Galen regarded its functions as primarily digestive in nature. In addition to its role in immunity the spleen functions as a filter for clearance of aging cells, foreign pathogens and other substances from the blood as well as a serving as a reservoir for blood elements.

The spleen is formed by alternating strata known as the white pulp, composed of lymphocytes and macrophages, and the red pulp, consisting of sinusoidal channels laden with RBCs, lymphoid elements and macrophages (Figure 6). Between the white and red pulp lies the marginal zone consisting of other lymphoid and macrophage lines. While macrophages in the white pulp are phagocytic and serve classic immune functions, red pulp macrophages perform scavenger and metabolic duties like RBC breakdown, bile pigment production, and iron recycling. Another subset, M2 macrophages, engage in regenerative and repair functions.

Figure 6: Contrast-enhanced CT image of the upper abdomen with zebra-striping of the spleen in early arterial phase. Lighter areas represent the highly vascular red pulp which opacifies first. Darker areas represent delayed opacification in the less vascular white pulp. Upon equilibration moments later the spleen becomes uniformly dense.

In the early 20th century surgeons increasingly performed splenectomy for enlargement of the spleen, aka hypersplenism. In the late 1920s reports began to trickle in describing cases of sudden, severe sepsis and death in otherwise healthy individuals who had undergone splenectomy years, sometimes decades, earlier. It wasn't until the 1950s that the causal connection became clear [499]. Now called OPSI, an acronym for 'overwhelming post-splenectomy infection', patients develop bacteremia caused by encapsulated microorganisms, usually without any obvious source of infection, along with septic shock and disseminated intravascular coagulation. Mortality rates are in the 50-70% range with death ensuing over 24-48 hours [500-502].

Over the next several decades clinical syndromes very much similar to that seen with OPSI were recognized in people with intact spleens and gradually the concept of 'functional hyposplenism' evolved [503-507]. Originally described in children with sickle cell anemia, it occurs more frequently than previously thought and can be seen in celiac disease, alcoholic liver disease, hepatic cirrhosis, lymphomas and a spectrum of AIDs including SLE, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, ulcerative colitis and autoimmune thyroiditis [508-516].

When stained blood smears from subjects with functional hyposplenism are examined microscopically so-called Howell-Jolly bodies, remnants of RBC nuclei normally removed by the spleen, along with 'pitted' RBCs containing defects in their membranes, are observed [517] (Figure 7). Radionuclide scans show decreased colloid uptake by the spleen suggesting impaired phagocytosis. The spleen is usually smaller than normal. Thus, in addition to an immune defect and increased susceptibility to infection, evidence points to impaired filtering by the spleen. Where does all this lead us?

Figure 7: Stained blood smear of Howell-Jolly bodies seen in hyposplenism. Howell-Jolly bodies represent basophilic remnants of RBC nuclear material that are normally removed by phagocytosis in the spleen.

(From: https://4.bp.blogspot.com/_EUkaWdQ4i64/TQjAJIV1XBI/AAAAAAAABds/D5U1oPMUP3E/s400/hn.jpg)

In the ancient framework blood was said to be composed of four humors. Health was defined as a state of balance (*krasis*) between the humors. Sickness, on the other hand, arose from imbalances with one or another humor present in excess. The humor known as black bile (*melan chole* or *atra bilis*) was a central concept in the ancient system that endured well into the early scientific era [518]. Based on natural correspondences derived from the Earth-Water-Air-Fire cosmology, it was partly empirical and partly speculative in origin. No other aspect of ancient thought has been the subject of more scorn and ridicule than black bile.

The ancients regarded black bile as a toxic substance that caused a wide range of disease. There were references to it in the Hippocratic text *On the Nature of Man* but we never get a clear idea of what black bile actually was or what it did. From the earliest time the spleen was regarded as a key player in its disposition. Galen, the 2nd century synthesizer of ancient medical thought, was the first to elucidate the nature of black bile.

Galen placed great emphasis on the role of the spleen in health and disease. He claimed it was

involved in the transformation and excretion of black bile. Black bile, he said, possessed a sharp, biting quality. It accumulated naturally during the fermentation of grapes into vinegar. It had a corrosive action that induced effervescence on contact with calcareous (chalky) earth. And he linked it to the incompletely digested food and juices in the condition we know as acid reflux and heartburn. But the ancients had no concept of acid and thus Galen simply referred to it as *oxys*. He claimed that the spleen attracted oxys to aid in digestion and, moreover, somehow used it for its own nourishment [519].

Soon after his discovery of lysosomes in the 1950s, Belgian biologist Christian de Duve under electron microscopy observed delivery of membrane-bound cellular material to lysosomes and coined the term autophagy to designate the orderly process by which cells self-digest [520-522]. During autophagy acid is actively concentrated in lysosomes and catabolic enzymes activated not unlike in the stomach. Autophagy not only culls aging and damaged cell structures but generates energy during periods of nutrient deficiency. Evidence suggests it represents a frontline defense against infection and, when deficient, is associated with various inflammatory disorders including the AIDs (Figure 8).

Figure 8: Electron microscopy of a macrophage containing phagosomes, light-colored inclusion bodies with ingested materials (arrows), lysosomes, dark-colored intracellular bodies (arrows), and phago-lysosomes in varying stages of digestion.

Many infectious agents, including the SARS-CoV-2, gain access to the body by colonizing epithelial cells where they attempt to reproduce and spread. Autophagy is the primary cellular response to such intrusions. Bacteria are enveloped in a membrane-bound structure, the phagosome, which fuses with acid-laden lysosomes to initiate digestion. If autophagy in epithelial cells is effective then further spread is averted; in cases where it is not the organism reproduces, initiates cell lysis, and spills into the extracellular fluid (ECF) space. During cell lysis, damage- and pathogen-associated molecules as well as cytokines are released which attract local macrophages [523-525].

Activated macrophages converge at the infection site and initiate phagocytosis to contain spread. Macrophages possess a multitude of acid-driven mechanisms by which to dispose of the infectious vector: the agent is walled-off in a sealed membrane limiting access to nutrients; release of polypeptides like defensin and cathelicidin destroy the outer bacterial membrane; acid and metals within the phagosome trigger the organism's own self-digestive enzyme systems; the catabolic degradation process amplifies to produce highly reactive substances like nitric oxide and free radicals which further degrade the ingested particle.

If such autophagy-driven mechanisms are successful then infection is contained and the immune response terminates; if insufficient then macrophages release pro-inflammatory cytokines to elicit support from circulating neutrophils and the adaptive immune system. Spread of infection thus involves successive breaches of barrier functions, first in epithelial cells, then macrophages in the ECF space, related to inadequate autophagy. Metchnikoff was correct. In chronic energy deficient states like the AIDs this process goes haywire.

Studies assessing splenic hypofunction in various AIDs like SLE, rheumatoid arthritis and inflammatory bowel disease for example, found impaired clearance of immune complexes and RBCs from the blood with inverse relation between the quantities of such substances and splenic hypofunction [526-548]. It is believed that renal damage accompanying SLE is related to deposition of Ag/Ab complexes in the kidneys due to impaired splenic filtration and saturation of the phagocytic system. The most dramatic example of deficient internal digestion is seen in a phenomenon known as neutrophil extracellular traps (NETs).

Neutrophil extracellular traps (NETs) are mesh-like structures that protrude from suicidal neutrophils intended to trap particulate materials [549-556] (Figure 9). Recruitment of neutrophils, highly phagocytic white blood cells, imputes a primary failure of macrophage functions in the spleen and ECF compartment. Increased numbers of NETs, called NETosis, are found in a wide variety of pathologic conditions including COVID-19 infection and the AIDs. NETs contain antigenic intracellular materials like DNA, RNA and oxidized proteins that trigger auto-Ab formation, worsening of endothelial dysfunction, and intravascular thrombosis.

Figure 9: Neutrophil extracellular traps (NETs). Web-like chromatin fibers expelled from suicidal neutrophils intended to trap and bind pathogenic materials. Excess accumulation of NETs, called NETosis, plays a pathogenic role in a wide range of inflammatory disorders, both infectious and non-infectious, as well as cancers, heart disease and stroke.

(From: https://www.researchgate.net/publication/349705669_Neutrophil-Induced_Liver_Injury_and_Interactions_Between_Neutrophils_and_Liver_Sinusoidal_Endothelial_Cells/figures?lo=1)

Autophagy impacts virtually every aspect of innate immune function. Impaired autophagy, in turn, is a hallmark of the AIDs [557-567]. At the intersection between the two pathologic states, we once again stumble upon microvascular dysfunction and inflammation [568-571]. Autophagy is an energy-driven process: acid is actively pumped into lysosomes *against* its concentration gradient by selective ion channels. In energy deficient states this mechanism is among the first to fail. Impaired autophagy is associated with mitochondrial and ion channel dysfunction [572-582]. Autophagic dysfunction is associated with elevated pro-inflammatory cytokines and other inflammatory markers [583-585].

Once this dynamic is set into motion a series of lethal events ensue: impaired mitochondrial function, compounded by lysosomal dysfunction, results in buildup of intracellular acid and reactive oxygen species. Progressive acidification of the cytoplasm impacts functions like protein synthesis and folding. Such events, in turn, trigger cytokine release, NLRP3 inflammasome formation, and cell death (apoptosis). Spillage of cell contents into the ECF space further aggravates already impaired phagocytic functions initiating a self-amplifying spiral of deterioration. This is likely what the ancient concept of black bile hinted at.

The digestive system thus represents an ensemble of functions that orchestrate the orderly breakdown, assimilation and elimination of organic substance. The two primary digestive organs, stomach and spleen, have conjoined origins in the upper left abdomen and use similar means centered around acid metabolism and acid-activated enzymes, i.e., black bile, to mediate their activities.

The two organs constitute an integrated functional nexus: the stomach takes in material from the outside which, upon decomposition, is drawn upward through intestinal veins to the liver where it is altered and subsequently transported through arteries to the ECF space for assimilation by cells; the splenic phase of the cycle, the internal digestive system proper, begins with the breakdown of intracellular materials via autophagy, extrusion of waste into the ECF space, uptake by phagocytic cells, and return of materials to the spleen for elimination or recycling. The two aspects of digestion are united through the cardiovascular system and blood. This leads us to consider one final aspect of splenic function.

A connection between the spleen and heart was first recognized around 1950 when researchers observed that electrical stimulation of splenic nerves improved ventricular function in laboratory dogs [586, 587]. They suggested that the spleen played a supporting role in cardiac function but the report generated little interest and sat on the shelf for over a half-century.

More recent studies found that during acute events like heart attack, stroke, infection and sepsis splenic volume decreases and, after a variable period of days, returns to its previous size. Splenic contraction appears to play an important role in such events and correlates with increased numbers of RBCs, monocytes, neutrophils, and lymphocytes in the blood. Studies suggest that splenic volume decreases in relation to disease severity. In recent years we thus find increasing references to the 'cardiosplenic axis' [588-592].

The spleen varies in size but on average is about 10×6×3cm and, due to its sinusoidal structure, is capable of greatly expanding and storing up to 20-30% of total blood volume [593-595]. In disease states like heart failure splenic size correlates positively with cardiac output and inversely with blood pressure. Decreased splenic size, influenced by hemodynamic factors such as blood volume and sympathetic nerve activity, is an independent predictor of poor outcomes in heart failure and other conditions [596-598] (Figure 10).

Figure 10: The many shapes and sizes of the spleen in health and disease. (Courtesy of Cynthia Wheeler, MD & Robert Hills, DO)

Larger than normal spleen size has been reported in elite endurance athletes and indigenous populations that engage in prolonged breath-holding activities beneath the sea surface [599]. Elite athletes not only have larger splenic volume but enhanced contractile capacity which, in response to exercise, dramatically increases blood RBC and hemoglobin levels. The spleen contracts during high-altitude mountain climbing as well, serving as a sort of 'auto-transfusion' to buffer the low-oxygen tension in the upper atmosphere [600-602].

Scientists claim such adaptive responses are intended to increase blood oxygen levels and while this is no doubt correct there is a more compelling reason. In earlier papers we show that the preconditioning (PC) phenomenon, a period of heightened systemic protection following periods of stress like ischemia or exercise, is mediated by enhanced energy generation in RBCs [603, 604]. The PC response is now recognized to be the most powerful protective mechanism yet discovered.

It appears likely that splenic contraction amplifies the effects of the PC phenomenon. It is also likely that its contraction occurs early in other systemic assaults like COVID-19 infection and provides an energy boost for immune cells that are also released. This would explain the generally milder course of illness in young and healthy people as well as higher morbidity and mortality in aging

and infirm populations in whom the PC response is blunted or absent. And it is likely that splenic contraction plays into the immune dysfunction seen following acute events like heart attack and stroke. To wit:

In response to systemic injury and infection large numbers of monocytes are released from the red pulp of the spleen, hone in on affected organs, and differentiate into macrophages. So-called M1 and M2 macrophages effect not only the phagocytic/ digestive phase of the response but are central to healing and regeneration [605-608].

Many chronic heart failure cases develop after heart attack and most of these result from failure to terminate the inflammatory response and transition to the healing phase. Much of the damage is mediated by cells originating in the spleen. Metabolic activity in the spleen increases after such events and is associated with activation of pro-inflammatory cells, increased C-reactive protein, and endothelial inflammation. Mitochondrial dysfunction in splenic derived macrophages promotes inflammation and suppresses tissue repair [609-616].

Lab studies in animals document the deleterious influence of splenic monocytes on promoting inflammation in a wide number of systemic conditions including stroke and heart attack, what is called the 'systemic inflammatory response syndrome' [617-619]. Splenectomy in mice with established heart failure reverses pathological cardiac changes and inflammation. Splenic cells transferred from mice with heart failure to healthy mice target the heart and induce immune-mediated inflammation and fibrosis. Recipient mice, in turn, undergo splenic remodeling and generate their own activated pro-inflammatory monocytes [620, 621].

None of these phenomena make a bit of sense unless there is already diminished energy availability in the blood, which brings us back full circle to microvascular dysfunction and inflammation. Inflammation begets more inflammation because it is a primary sign of diminished energy generation by the cardiovascular system. The spleen and internal digestive system, intimately related to the heart and blood, cannot complete its assigned functions without sufficient energy, highlighting a central tenet of ancient medicine: *omnia incipit in sanguine,* everything begins in the blood. Therein lies the unity of immunity.

THE GREAT DELUSION

Experimental medicine is exactly what its name implies. Since the turn of the 20th century scientists have engaged in a grand experiment upon populations across the globe to test their hypotheses regarding the causal primacy of cellular and molecular mechanisms in the body. Over the past century science dominated intellectual discourse in modern societies and, as observed in the arrogant commentary of Sir Peter Medawar, sought to establish scientific knowledge as invincible and the experimental method as a gold standard for attainment of such knowledge. This was pure delusion.

Early on in the experimental science experiment a rash of interpretive errors regarding cardiovascular function, organization of the nervous system, immune theory, and the primacy of genetics became deeply enmeshed in its theory structure making any kind of unifying synthesis all but impossible. Medical science became trapped in a conceptual labyrinth of its own design and its quest for unity and insight as elusive as the mythical Holy Grail. In the process science became a never-ending 20th century fable.

Such developments correspond to science historian Thomas Kuhn's notion of a paradigm collapse. Once a science reaches the point where

431

its knowledge no longer accurately explains phenomena, and its theory structure littered with errors and internal contradiction, it becomes useless and obsolete. Such is the current state of scientific medical knowledge. And once a theory is shown to be wrong, a logical corollary follows that it was wrong from the beginning, which is to say scientists should have been more critical and circumspect of the theories they propounded.

By 1970, ten years after receiving the Nobel Prize for his Clonal Selection Theory, Macfarlane Burnet had soured on experimental medicine. In *Genes, Dreams and Realities* he argued that the contribution of laboratory science in unlocking the problem of disease had come to an end and that further research would amount to little more than filling in of details. Most of the breakthroughs in 20th century medicine, he noted, were observational in nature and not based on experiment.

Burnet claimed that 'too much sensational material was being written about the future significance of discoveries in molecular biology'. He pointed to the increasing burden of chronic diseases and lack of meaningful change in their outcomes in the previous 3-4 decades. Modern science, he wrote, 'is by no means the triumphal march toward perpetual health and well-being' as popular accounts would suggest. By this time science had become a collectively shared cultural delusion. And far from stunning breakthroughs he warned that molecular science 'might release some new and nasty problems on a world that already has more than it can cope with'.

Fifty years on Burnet looks like a minor prophet. An explosive epidemic of chronic diseases has spread across the planet on a scale unrivaled in history. Over the last half of the 20th century, one observes striking parallel rises in the burden of chronic disease and healthcare costs in all industrialized nations. Today, 120 years since the advent of the modern therapeutic era, medical science has yet to cure a single class of disease, and its physicians do little more than manage the progressive and unrelenting course of these intractable conditions.

No matter how scientists may wish and hope to pull the rabbit out of the hat one more time with their magic bullets there is no *Plus Ultra*. Scientific knowledge has reached its limit and the experimental era is dead. The length of time spent beating a dead horse has no bearing on the degree of death. Meanwhile societies must come to terms with this monumental failure and begin to devise and implement solutions to confront a looming disaster.

REFERENCES

1. Travels and travails of autoimmunity: A historical journey from discovery to rediscovery. Mackay IR. *Autoimmunity Rev.* 2010;A251–A258.

2. Autoimmunity versus horror autotoxicus: The struggle for recognition. Silverstein AM. *Nature Immunol.* 2001;vol 2(4):279-81.

3. *A History of Immunology.* Arthur M. Silverstein publ. Academic Press, Inc. 1989.

4. *The Limits of Science.* P.B. Medawar. Harper & Row, Publishers. 1984.

5. Energy dynamics in chronic heart failure, chronic kidney disease & the cardiorenal syndrome: A new causal paradigm. Thorp KE, Thorp JA, Northrup C, et al. *G Med Sci.* 2023 May;4(1):290-347.

6. Energy Dynamics in Dementia & the Neurodegenerative Diseases: A New Causal Paradigm. Thorp KE, Thorp JA, Northrup C, et al. *G Med Sci.* 2023;4(1):348-405.

7. *Galen's System of Physiology and Medicine.* Rudolph E. Siegel publ. S. Karger. 1968.

8. Mechanisms of autoimmunity in human diseases: a critical review of current dogma. Benson RA, Brewer JM, Platt AM. *Curr Opin Rheumatol.* 2014 Mar;26(2):197-203.

9. Prediction and prevention of autoimmune disease in the 21st century: A review and preview. Rose NR. *Am J Epidemiol.* 2016;183(5):403-6.

10. Human autoimmune diseases: A comprehensive update. Wang L, Wang F-S, Gershwin ME. *J Intern Med.* 2015 Oct;278(4):369-95.

11. Autoimmune overlap syndromes. Woodward J, Neuberger J. *Hepatology.* 2001 Apr; 33(4):994-1002.

12. A case of overlap syndrome with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis and secondary Sjögren's syndrome. Woodward J, Neuberger J, et al. *Rheumatol Int.* 2006 Jul;26(9):841-45.

13. Genetic overlap between type 1 diabetes and other autoimmune diseases. Márquez A, Martín J. *Semin Immunopathol.* 2022 Jan;44(1):81-97.

14. Autoimmune hepatitis—SLE overlap syndrome. Koshy JM, John M. *J Assoc Physic India.* 2012 Sep;60:59-60.

15. Overlap autoimmune syndrome: primary progressive multiple sclerosis, primary biliary cirrhosis, Raynaud phenomenon with digital necrosis. Koshy JM, John M. *Acta Neurol Belg.* 2023 Feb;123:283-85.

16. Rhupus: A systematic literature review. Antonini L, Le Mauff B, Marcelli C, et al. *Autoimmun Rev.* 2020 Sep;19(9):102612.

17. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): A Delphi study. Ben-Chetrit E, Gattorno M, Gul A, Kastner DL, et al. *Ann Rheum Dis.* 2018 Nov; 77(11):1558-1565.

18. The pathogenesis of psoriatic arthritis. Veale DJ, Fearon U. *Lancet.* 2018; 391(10136):2273-2284.

19. Extraintestinal Manifestations of Inflammatory Bowel Disease. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. *Inflamm Bowel Dis.* 2015;21:1982–1992.

20. Inflammatory bowel disease associated arthropathy. Arvikar SL, Fisher MC. *Curr Rev Musculoskelet Med.* 2011;4:123–131.

21. Genetics of autoimmune diseases: Perspectives from genome-wide association studies. Kuch Y. Int Immunol. 2016 Apr;28(4):155-61.

22. Gender differences in autoimmune disease. Ngo ST, Steyn FJ, McCombe PA. *Front Neuroendocrinol.* 2014 Aug;35(3):347-69.

23. Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. Miller FW, Alfredsson L, Costenbader KH, Kamen DL, et al. *J Autoimmun.* 2012 Dec;39(4):259-71.

24. Seasonality and autoimmune diseases: The contribution of the four seasons to the mosaic of autoimmunity. Watad A, Azrielant S, Bragazzi NL, Sharif K, et al. *J Autoimmun.* 2017 Aug; 82:13-30.

25. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Perez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, et al. *Expert Opin Drug Saf* 2017 Nov;16(11):1255-1271.

26. Biologics-induced autoimmune diseases. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. BIOGEAS study group. *Curr Opin Rheumatol.* 2013 Jan;25(1):56-64.

27. Vaccination and induction of autoimmune diseases. Toussirot É, Bereau M. Inflamm *Allergy Drug Targets.* 2015;14(2):94-8.

28. Autoimmune diseases and infections: Controversial issues. Baio P, Brucato A, Buskila D, Gershwin ME, et al. *Clin Exp Rheumatol.* 2008; 26(1 Suppl 48):S74-80.

29. Reactive arthritis (Reiter's syndrome). Barth WF, Segal K. *Am Fam Physician*. 1999 Aug; 60(2):499-503, 507.

30. Reactive arthritis or Reiter's syndrome and B51-associated seronegative spondyloarthropathy. S Kobayashi, S Ando. *Intern Med.* 2000 Feb;39(2):89.

31. Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic *Escherichia coli* (DEC). Tuompo R, Lääveri T, Hannu T, Pakkanen SH, et al. *Ann Rheum Dis.* 2020 May;79(5):605-611.

32. Reactive arthritis: Update. Bentalab I, Abdelghani KB, Rostom S, Bouchra A, Laatar A, Bahiri R. Current Clinical Microbiology Reports. 2020.

33. Behçet's disease: Review with emphasis on dermatological aspects. Scherrer MA, Rocha VB, Garcia LC. *An Bras Dermatol.* Jul-Aug 2017;92(4):452-464.

34. Potential Infectious Etiology of Behçet's Disease. Galeone M, Coluccii R, D'Erme AM, Moretti S, *Lotti T. Patholog Res Int. 2012;2012:595380.*

35. Autoinflammatory syndromes. Galeazzi M, Gasbarrini A, Ghirardello S, Grandemange H, et al. *Clin Exp Rheumatol.* 2006;24(Suppl 40):S79-85.

36. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Smatti MK, Cyprian FS, Nasrallah GK, et al. *Viruses.* 2019;11:762.

37. The role of viral infections in the development of autoimmune diseases. Hussein HM, Rahal EA. *Crit Rev Microbiol.* 2019;45:394–412.

38. Virus infection, antiviral immunity, and autoimmunity. Getts DR, Chastain EML, Terry RL, Miller SD. *Immunol Rev.* 2013;255:197–209.

39. Antiviral immune responses: Triggers of or triggered by autoimmunity? Münz C, Lünemann JD, Getts MT, Miller SD. *Nat Rev Immunol.* 2009;9:246–258.

40. Myositis as a manifestation of SARS-CoV-19. Beydon M., Chevalier K., Al Tabaa O, et al. *Ann Rheum Dis.* 2021;80:e42.

41. Case Report of COVID-19 in an Elderly Patient: Could SARS-CoV2 Trigger Myositis? Sacchi MC, Tamiazzo S, Lauritano EC, et al. *Eur. Rev. Med. Pharmacol. Sci.* 2020;24:11960–11963.

42. Clinical presentations of pain in patients with COVID-19 infection. Murat S, Dogruoz Karatekin B, Icagasioglu A, et al. *Ir J Med Sci.* 2021 Aug;190(3):913-17.

43. Reactive arthritis after COVID-19 vaccination. An QJ, Qin DA, Pei JX. *Hum Vaccin Immunother.* 2021 Sep;17(9):2954-56.

44. Pain symptoms in patients with coronavirus disease (COVID-19): A literature review. Weng LM, Su X, Wang XQ. *J Pain Res.* 2021 Jan;14:147-59.

45. Neuromuscular presentations in patients with COVID-19. Paliwal VK, Garg RK, Gupta A, et al. *Neurol Sci.* 2020 Nov;41(11):3039-56.

46. Cutaneous manifestations of SARS-CoV-2 infection. Huynh T, Sanchez-Flores X, Yau J, et al. *Am J Clin Dermatol.* 2022 May;23(3):277-86.

47. COVID-19 skin manifestatins: An update. Sanchez-Flores X, Huynh T, Huang JT. *Curr Opin Pediatr.* 2021 Aug;33(4):380-86.

48. COVID-19 and cutaneous manifestations: A review of published literature. Martora F, Villani A, Fabbrocini G, et al. *Cosmet Dermatol.* 2023 Jan;22(1):4-10.

49. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Pons S, Fodil S, Azoulay E, et al. *Crit Care.* 2020;24(1):353.

50. Understanding COVID-19: In the end is it endothelium—what else? Lüscher TF. *Eur Heart J.* 2020;41(32):3023-27.

51. COVID-19 is, in the end, an endothelial disease. Libby P, Lüscher T. *Eur Heart J.* 2020; 41(32):3038-44.

52. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Gavriilaki E, Anyfanti P, Gavriilaki M, et al. *Curr Hypertens Rep.* 2020;22(9):63.

53. Endothelial dysfunction in COVID-19: A position paper of the ESC Working Group for Atherosclerosis and the ESC Council of Basic Cardiovascular Science. Evans PC, Rainger GE, Mason JC, et al. *Cardiovasc Res.* 116(14):2177-84.

54. Endothelial cells and SARs-CoV-2: An intimate relationship. Barbosa LC, Gonçalves TL, de Araujo LP, et al. *Vasc Pharmacol.* 2021;137:106829.

55. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Nägele MP, Haubner B, Tanner FC, et al. *Atherosclerosis.* 2020;314:58-62.

56. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Del Turco S, Vianello A, Ragusa R, et al. *Thromb Res.* 2020;196:143-51.

57. COVID-19 and the Unraveling of Experimental Medicine - Part I. Thorp KE, Thorp JA, Thorp EM. *G Med Sci.* 2022;3(1):015-045.

58. COVID-19: energy, protein folding & prion disease. Thorp KE, Thorp JA, Thorp EM, Thorp MM, Walker PR. *G Med Sci.* 2022;3(1):0179-0206.

59. The cytokine storm and COVID-19. Hu B, Huang S, Yin L. *J Med Virol.* 2021 Jan; 93(1):250-56.

60. Cytokine storm in COVID-19: Immunopathogenesis and therapy. Zanza C, Romenskaya T, Manetti AC, et al. *Medicina (Kaunas).* 2022 Jan;58(2):144.

61. The pathogenesis and treatment of the 'cytokine storm' in COVID-19. Ye Q, Wang B, Mao J. *J Infect.* 80(6):607-613.

62. Immunopathogenesis and treatment of cytokine storm in COVID-19 storm. Kim JS, Lee JY, Yang JW, et al. *Theranostics.* 2021 Jan;11(1):316-29.

63. COVID-19 infection: An overview on cytokine storm and related interventions. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. *Virol J.* 2022 May;19(1):92.

64. Partners in crime: Autoantibodies complicit in COVID-19 pathogenesis. Zebardast A, Hasanzadeh A, Ebrahimian Shiadeh SA, et al. *Rev Med Virol.* 2023 Mar;33(2):e2412.

65. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Gazzaruso C, Stella NC, Mariani G, et al. *Clin Rheumatol.* 2020; 39:2095–2097.

66. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Zhou Y, Han T, Chen J, et al. *Clin Transl Sci.* 2020;13:1077–1086.

67. Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19. Woodruff MC, Ramonell RP, Saini AS, et al. *medRxiv.* 2021.

68. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Bastard P, Rosen LB, Zhang Q, et al. *Science.* 2020;370:eabd4585.

69. New Onset of autoimmune diseases following COVID-19 diagnosis. Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. *Cells.* 2021 Dec;10(12):3592.

70. A concomitant diagnosis of COVID-19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: A new case report. Hali F, Jabri H, Chiheb S, et al. *Int J Dermatol.* 2021;60:1030–1031.

71. Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Gracia-Ramos AE, Saavedra-Salinas MA. *Rheumatol Int.* 2021;41:799–809.

72. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Cardoso EM, Hundal J, Feterman D, et al. *Clin Rheumatol.* 2020;39:2811–2815.

73. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. Slimani Y, Abbassi R, El Fatoiki F, et al. *J Med Virol.* 2021;93:1184–1187.

74. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Bonometti R, Sacchi MC, Stobbione P, et al. *Eur Rev Med Pharmacol Sci.* 2020;24:9695–9697.

75. Onset of rheumatoid arthritis after COVID-19 infection: Coincidence or connected? Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, et al. *Rheum Dis.* 2021 Aug;80(8):1096-98.

76. Inflammatory arthritis post COVID-19 infection. Deeb M, Moloney PB, McCarthy G, et al. *Ir J Med.* 2022 Jan;115(1):525.

77. New-onset autoimmune phenomena post-COVID-19 vaccination. Chen Y, Xu Z, Wang P, et al. *Immunology.* 2022 Apr;165(4):386-401.

78. Flare of rheumatoid arthritis after COVID-19 vaccination. Terracina KA, Tan FK. *Lancet Rheumatol.* 2021 Jul;3(7):e469-70.

79. Reactive Arthritis in a 37-Year-Old Female With SARS-CoV2 Infection. Danssaert Z, Raum G, Hemtasilpa S. *Cureus.* 2020;12:e9698.

80. Reactive arthritis after COVID-19 infection. Ono K, Kishimoto M, Shimasaki T, et al. *RMD Open.* 2020;6:e001350.

81. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. Schenker HM, Hagen M, Simon D, et al. *Rheumatology.* 2021;60:479–480.

82. Reactive Arthritis After COVID-19 Infection. Jali I. *Cureus.* 2020;12:e11761.

83. Transient monoarthritis and psoriatic skin lesions following COVID-19. De Stefano L, Rossi S, Montecucco C, et al. *Ann. Rheum. Dis.* 2020;2020:218520.

84. Viral arthritis and COVID-19. Parisi S, Borrelli R, Bianchi S, et al. *Lancet Rheumatol.* 2020;2:e655–e657.

85. Case of acute arthritis following SARS-CoV-2 infection. Yokogawa N, Minematsu N, Katano H, et al. *Ann Rheum Dis.* 2021;80:e101.

86. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Perrot L, Hemon M, Busnel J-M, et al. *Lancet Rheumatol.* 2021;3:6–8.

87. COVID-19 and Myositis: What We Know So Far. Saud A., Naveen R., Aggarwal R, et al. *Curr Rheumatol Rep.* 2021;23:63.

88. Orbital myositis and scleritis after anti-SARS-CoV-2 mRNA vaccines: A report of three cases. Savino G, Gambini G, Scorcia G, et al. *Eur J Ophthalmol.* 2022 Sep;11026721221123780.

89. Coexistence of pancytopenia and myositis after developing COVID-19. Okayasu T, Ohta R, Igarashi M, et al. *Cureus.* 2022 Jul;14(7):e26978.

90. Myositis as a manifestation of SARS-CoV-19. Beydon M., Chevalier K., Al Tabaa O, et al. *Ann Rheum Dis.* 2021;80:e42.

91. Myopericarditis and myositis in a patient with COVID-19: A case report. Shabbir A, Camm CF, Elkington A, et al. *Eur Health J Case Rep.* 2020;4:1–6.

92. Delayed-onset Necrotizing Myositis following COVID-19 Infection. Lokineni S, Mortezavi M. *Eur J Case Rep Intern Med.* 2021;8:002461.

93. COVID-19 IgG-related autoimmune inflammatory necrotizing myositis. Veyseh M, Koyoda S, Ayesha B. *BMJ Case Rep.* 2021;14:e239457.

94. Case Report of COVID-19 in an Elderly Patient: Could SARS-CoV2 Trigger Myositis? Sacchi MC, Tamiazzo S, Lauritano EC, et al. *Eur. Rev. Med. Pharmacol. Sci.* 2020;24:11960–11963.

95. First manifestation of adult-onset Still's disease after COVID-19. Bamidis AD, Koehler P, di Cristanziano V, et al. *Lancet Rheumatol.* 2021;3:e319–e321.

96. Myocarditis following COVID-19 mRNA vaccination. Abu Mouch S, Roguin A, Hellou E, et al. *Vaccine.* 2021 Jun; 39(29):3790-93.

97. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. Montgomery J, Ryan M, Engler R, et al. *JAMA Cardiol.* 2021 Oct;6(10):1202-06.

98. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Fazlollahi A, Zahmatyar M, Noori M, et al. *Rev Med Virol.* 2022 Jul;32(4): e2318.

99. Myocarditis following COVID-19 vaccination: A systematic review. Shaheen N, Ramadan A, Shaheen A, et al. Cureus. 2023 Apr 22;15(4):e37999.

100. Vasculitis changes in COVID-19 survivors with persistent symptoms: An [18F] FDG-PET/CT study. Sollini M, Ciccarelli M, Cecconi M, et al. *Eur J Nucl Med Mol Imaging.* 2021;48:1460–1466.

101. Viral infections associated with Kawasaki disease. Chang L-Y, Lu C-Y, Shao P-L, et al. *J Formos Med Assoc.* 2014;113:148–154.

102. Concurrent Respiratory Viruses and Kawasaki Disease. Turnier JL, Anderson MS, Heizer HR, et al. *Pediatrics.* 2015;136:e609–e614.

103. Distinctive Features of Kawasaki Disease Following SARS-CoV-2 Infection: A Controlled Study in Paris, France. Toubiana J, Cohen JF, Brice J, et al. *J Clin Immunol.* 2021;41:526–535.

104. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: A cohort study. Toubiana J, Cohen JF, Brice J, et al. *Lancet Rheumatol.* 2021;3:e574–e584.

105. New-onset type 1 diabetes and severe acute respiratory syndrome coronavirus 2 infection. Anindya R, Rutter GA, Meur G. *Immunol Cell Biol.* 2023 Mar;101(3):191-203.

106. New onset diabetes, type 1 diabetes and COVID-19. Boddu SK, Aurangabadkar G, Kuchay MS. *Diabetes Metab Syndr.* 2020 Nov;14(6):2211-17.

107. New-onset type I diabetes in Finnish children during the COVID-19 pandemic. Salmi H, Heinonen S, Hästbacka J, et al. *Arch Dis Child.* 2022 Feb;107(2):180-85.

108. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. Sakurai K, Narita D, Saito N, et al. *J Diabetes Investig.* 2022 Jul;13(7):1290-92.

109. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort form the US using the Cerner Real-World Data. Qeadan F, Tingey B, Egbert J, et al. *PLoS One.* 2022 Apr;17(4):e0266809.

110. Increases in the diagnosis and severity of presentation of pediatric type 1 and type 2 diabetes mellitus during the COVID-19 pandemic. Marks BE, Khilnani A, Meyers A, et al. *Horm Res Paediatr.* 2021;94(7):275-84.

111. Association of CNS demyelination and COVID-19 infection: An updated systematic review. Ismail II, Salama S. *J Neurol.* 2022 Feb;269(2):541-76.

112. Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. Feizi P, Sharma K, Pasham SR, et al. *J Neuroimmunol.* 2022 Oct;371:577939.

113. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. Toljan K, Amin M, Kunchok A, et al. *J Neuroimmunol.* 2022 Jan;362:577785.

114. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Garjani A, Middleton RM, Hunter R, et al. *Mult Scler Relat Disord.* 2021 Jul;52:102939.

115. Multiple sclerosis relapse following COVID-19 vaccination: A case report and literature review. Kataria S, Rogers S, Bilal U. *Cureus.* 2022 Jan;14(1):e21374.

116. A systematic review of cases of CNS demyelination following COVID-19 vaccination. Ismail II, Salama S. *J Neuroimmunol.* 2022 Jan;362:577765.

117. Spinal cord involvement in COVID-19. A review. Ismail II, Salama S. *Spinal Cord Med.* 2023 May;46(3):3990-404.

118. Pediatric autoimmune encephalitis following COVID-19 infection. Hilado M, Banh M, Homans J, et al. *J Child Neurol.* 2022 Mar;37(4):268-72.

119. Autoimmune encephalitis after SARS-CoV-2 infection: Case frequency, findings, and outcomes. Valencia Sanchez C, Theel E, et al. *Neurology.* 2021 Dec;97(23):e2262-68.

120. Autoimmune encephalitis associated with COVID-19: A systematic review. Nabizadeh F, Balabandian M, Sodeifian F, et al. *Mult Scler Relat Disord.* 2022 Jun;62:103795.

121. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Dalakas MC. *Neurol Neuroimmunol Neuroinflamm.* 2020 Jun;7(5):e781.

122. Guillain-Barré syndrome associated to COVID-19 infection: A review of published case reports. Zuberbühler P, Conti ME, León-Cejas L, et al. *Rev Neurol.* 2021 Mar;72(6):203-12.

123. Guillain-Barré syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. *J Neurol.* 268(4):1133-70.

124. Guillain-Barré syndrome after COVID-19 vaccination. McKean N, Chircop C. *BMJ Case Rep.* 2021 Jul;14(7):e244125.

125. Guillain-Barré syndrome associated with COVID-19 vaccination. Shao SC, Wang CH, Chang KC, et al. *Emerg Infect Dis.* 2021 Dec;27(12):3175-78.

126. Systematic review of COVID-19 and autoimmune thyroiditis. Tutal E, Ozaras R, Leblebicioglu H. *Travel Med Infect Dis.* 2022 May;47:102314.

127. Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves' disease: A case report. Rubinstein TJ. *Ophthalmic Plast Reconstr Surg.* 2021 Nov;37(6):e221-23.

128. COVID -19 and thyroid diseases: A bidirectional impact. Duntas LH, Jonklaas J. *J Endocr Soc.* 2021 Apr;5(8):bvab076.

129. Graves' disease after exposure to the SARS-CoV-2 vaccine: A case report and review of the literature. Takedani K, Notsu M, Ishiai N, et al. *BMC Endocr Disord.* 2023 Jun;23(1):132.

130. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. Vuille-Lessard É, Montani M, Bosch J, et al. *J Autoimmun.* 2021 Sep;123:102710.

131. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, et al. *J Autoimmun.* 2021 Sep;123:1102706.

132. Autoimmune hepatitis after COVID-19 vaccination. Zheng H, Zhang T, Xu Y, et al. *Front Immunol.* 2022 Nov;13:1035073.

133. Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence. Garrido I, Lopes S, Simões MS, et al. *J Autoimmun.* 2021 Dec;125:102741.

134. Autoimmune hepatitis following vaccination for SARS-CoV-2 in Korea: Coincidence or autoimmunity? Kang SH, Kim MY, Cho MY, et al. *Korean Med Sci.* 2022 Apr;37(15):e116.

135. COVID-19 and immune-mediated RBC destruction. Jacobs JW, Booth GS. *Am J Clin Pathol.* 2022 Jun;157(6):844-51.

136. Complement mediated hemolytic anemias in the COVID-19 era: Case series and review of the literature. Fattizzo B, Pasquale R, Bellani V, et al. *Front Immunol.* 2021 Nov;12:791429.

137. Autoimmune hemolytic anemia: A late presentation of post-COVID-19 syndrome. Al Khoufi E, Al-Muhainy B, Algadeeb K, et al. *Oman Med J.* 2023 Jan;38(1):e467.

138. Severe autoimmune hemolytic enemia following receipt of SARS-CoV-2 mRNA vaccine. Gadi SRV, Brunker PAR, Al-Samkari H, et al. *Transfusion.* 2021 Nov;61(11):3267-71.

139. Autoimmune hemolytic anemia after mRNA COVID vaccine. Fatima Z, Reece BRA, Moore JS, et al. *J Investig Med High Impact Case Rep.* 2022 Jan;10:23247096211073258.

140. COVID-19 and implications for dermatological and allergological diseases. Buhl T, Beissert S, Gaffal E, et al. *Dtsch Dermatol Ges.* 2020 Aug;18(8):815-24.

141. Cutaneous manifestations related to the COVID-19 pandemic: A review article. Molaee H, Allahyari F, Emadi SN, et al. *Cutan Ocul Toxicol.* 2021 Jun;40(2):168-74.

142. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Seirafianpour F, Sodagar S, Pour Mohammad A, et al. *Dermatol Ther.* 2020 Nov;33(6):e13986.

143. COVID-19 pandemic and the skin: What should dermatologists know? Darlenski R, Tsankov N. *Clin Dermatol.* 2020 Nov;38(6):785-87.

144. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. Bellinato F, Maurelli M, Gisondi P, et al. *J Clin Med.* 2021 Nov;10(22):5344.

145. A systemic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Kouranloo K, Dey M, Elwell H, et al. *Rheumatol Int.* 2023 Jul;43(7):1221-43.

146. Case Report: Systemic Sclerosis After Covid-19 Infection. Fineschi S. *Front Immunol.* 2021; 12:686699.

147. Diffuse cutaneous systemic sclerosis following SARS-CoV-2 vaccination. Cole A, Thomas R, Goldman N, et al. *J Autoimmun.* 2022 Apr;128:102812.

148. Systemic sclerosis and COVID-19 vaccines: A SPIN cohort study. Gordon JK, Showalter K, Wu Y, et al. *Lancet Rheumatol.* 2022 Apr;4(4):e243-46.

149. Sarcoidosis developing after COVID-19: A case report. Somboonviboon D, Wattanathum A, Keorochana N, et al. *Respirol Case Rep.* 2022 Aug;10(9):e01016.

150. New onset sarcoidosis after COVID-19 infection. Rabufetti A, Borradori L, Heidemeyer K, et al. *J Eur Acad Dermatol Venereol.* 2022 Oct;36(10):e756-59.

151. Cutaneous and pulmonary manifestations of sarcoidosis triggered by coronavirus disease 2019 infection. Rodrigues FT, Quirino RM, Gripp AC. *Rev Soc Bras Med. Trop.* 2022 Apr;55:e06472021.

152. Sarcoidosis and COVID-19: At the cross-road between immunopathology and clinical manifestation. Tana C, Cinetto F, Mantini C, et al. *Biomedicines.* 2022 Oct;10(10):2525.

153. A novel development of sarcoidosis following COVID-19 vaccination and a literature review. Numakura T, Murakami K, Tamada T, et al. *Intern Med.* 2022 Oct;61(20):3101-06.

154. COVID-19 mRNA vaccine-associated uveitis leading to diagnosis of sarcoidosis: Case report and review of the literature. Matsuo T, Honda H, Tanaka T, et al. *J Investig Med High Impact Casr Rep.* 2022 Jan;10:23247096221086450.

155. Biologic therapy for autoimmune diseases: An update. Rosman Z, Shoenfeld Y, Zandman-Goddard G. *BMC Med.* 2013;11:88.

156. Emerging cell and cytokine targets in rheumatoid arthritis. Burmester GR, Feist E, Dorner T. *Nat Rev Rheumatol.* 2014;10(2):77-88.

157. Alterations in immune function with biologic therapies for autoimmune disease. *J Allergy Clin Immunol.* Her M, Kavanaugh A. 2016;137(1):19-27.

158. Injection site reactions with the use of biological agents. Thomaidou E, Ramot Y. *Dermatol Ther.* 2019 Mar;32(2)e12817.

159. Acute infusion reactions induced by monoclonal antibody therapy. Maggi E, Vultaggio A, Matucci A. *Expert Rev Clin Immunol.* 2011 Jan;7(1):55-63.

160. Hypersensitivity and immunologic reactions to biologics: Opportunities for the allergist. Khan DA. *Ann Allergy Asthma Immunol.* 2016 Aug;117(2):115-20.

161. Hypersensitivity reactions during treatment with biological agents. Puxeddu I, Caltran E, Rocchi V, et al. *Clin Exp Rheumatol.* 2016 Jan;34(1):129-32.

162. Biologic agents and tuberculosis. Dobler CC. *Microbiol Spectr.* 2016 Dec;4(6).

163. Adverse side-effects to biological agents. Pichler WJ. Allergy. 2006;61(8):912-20.

164. The complex clinical picture of side effects to biologicals. Hausmann OV, Seitz M, Villiger PM, et al. *Med Clin North Am.* 2010 Jul;94(4):791-804.

165. Adverse reactions to biologic agents and their medical management. Boyman O, Comte D, Spertini F. *Nat Rev Rheumatol.* 2014;10(10):612-27.

166. Management of adverse reactions to biologic agents. Isabwe GAC, de Las Vecillas Sanchez L, et al. *Allergy Asthma Proc.* 2017 Nov;38(6):409-18.

167. Biologic therapies and autoimmune phenomena. Drosos AA, Pelechas E, Kaltsonoudis E, et al. *Mediterr J Rheumatol.* 2021 Jun;32(2):96-103.

168. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Vaz JLP, Andrade CAF, Pereira AC, et al. *Rev Bras Reumatol.* 2013;53(4):358-64.

169. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Eriksson C, Engstrand S, Sundqvist KG, et al. Ann Rheum Dis. 2005;64:403-7.

170. Autoimmune diseases induced by TNF-targeted therapies. Ramos-Casals, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. *Best Pract Res Clin Rheumatol.* 2008;22(5):847-61.

171. The complexity of adverse side-effects to biological agents. Aubin F, Carbonnel F, Wendling D. *Crohn's Colitis.* 2013 May;7(4):257-62.

172. Autoimmune diseases induced by biological agents: A double-edged sword? Ramos-Casals M, Perez-Alvarez R, Diaz Lagares C, et al. Autoimmun Rev. 2010;9(3):188-93.

173. Biologics-induced autoimmune diseases. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. *Curr Opin Rheumatol.* 2013;25(1):56-64.

174. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. De Bandt M, Sibilia J, Le Loet X, et al. *Arthritis Res Ther.* 2005;7(3):R545-R551.

175. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Costa MF, Said NR, Zimmermann B. *Semin Arthritis Rheum.* 2008;37(6):381-7.

176. Anti-TNF-induced lupus. Williams EL, Gadola S, Edwards CJ. *Rheumatology (Oxford)* 2009;48(7):716-20.

177. Diverse patterns of anti-TNF-α induced lupus: Case series and review of the literature. Shovman O, Tamar S, Amital H, et al. *Clin Rheumatol.* 2018;37:563-8.

178. Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Mounach A, Ghazi M, Nouijai A, et al. *ClinExp Rheumatol.* 2008 Nov;26(6):1116-18.

179. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Costa MF, Said NR, Zimmermann B. *Semin Arthritis Rheum.* 2008;37(6):381-7.

180. Anti-TNF-induced lupus. Williams EL, Gadola S, Edwards CJ. *Rheumatology (Oxford).* 2009;48(7):716-20.

181. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. De Gannes GC, Ghoreishi M, Pope J, et al. *Arch Dermatol.* 2007;143(2):223-31.

182. Cutaneous autoimmune phenomena of the anti-TNFα biosimilars. Casebased Review. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. *Curr Rheumatol Rev.* 2021;17(2):267-70.

183. Anti-TNF therapy induced arthritis in patients with inflammatory bowel disease. Reilly E, Edwards C, Mackay K. *Rheumatology (Oxford).* 2015;54(suppl 1):i94.

184. Do TNF-blockers reduce or induce uveitis? Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, et al. *Rheumatology (Oxford).* 2008;47(5):731-2.

185. Increased risk of developing Crohn's disease or ulcerative colitis in 17018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Korzenik J, Larsen MD, Nielsen F. *Aliment Pharmacol Ther.* 2019;50(3):2890294.

186. Monoclonal antibody therapy-associated neurologic disorders. Bosch X, Saiz A, Ramos-Casals M. *Nat Rev Neurol.* 2011; 7:165-72.

187. Demyelinating disease in patients treated with TNF antagonists in rheumatology: Data from BIOBADASER, a pharmacovigilance database, and a systematic review. Fernandez-Espartero MC, Perez-Zafrilla B, Nananjo A, Esteban C, et al. *Semin Arthritis Rheum.* 2011;40(4):330-7.

188. Demyelinating disease following anti-TNFα treatment: A causal or coincidental association? Report of four cases and review of the literature. Andreadou E, Kemanetzoglou E, Brokalaki CH, et al. *Case Rep Neurol Med.* 2013;2013:671935.

189. Optic neuritis after infliximab therapy. Faillace C, de Almeida JRM, de Carvalho JF. *Rheumatol Int.* 2013;33:1101-3.

190. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies. Molloy ES, Calabrese LH. *Arthritis Rheum.* 2012;64(9):3043-51.

191. A review of neurologic complications of biologic therapy in plaque psoriasis. Lin EJ, Reddy S, Shah VV, Wu JJ. *Cutis.* 2018;101(1):57-60.

192. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: A rare event. Berger JR, Malik V, Lacey S, et al. *J Neurovirol.* 2018:24(3):323-31.

193. Increase risk of multiple sclerosis in patients with psoriasis disease: An evidence of observational studies. Islam MM, Poly TN, Yang HC, et al. *Neuroepidemiology.* 2019;52(3-4):152-60.

194. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Fiorino G, Danese S, Pariente B, et al. *Autoimmun Rev.* 2014;13(1):15-9.

195. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. *Arthritis Rheum.* 2005;52(8):2513-8.

196. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Karamanakos A, Vergou T, Panopoulos S, et al. *Eur J Dermatol.* 2021 Jun;31(3):307-17.

197. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Kremenevski I, Sander O, Sticherling M, et al. *Dtsch Arztebl Int.* 2022 Feb;119(6):88-95.

198. Paradoxical reactions: Anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Puig L. *Curr Prob Dermatol.* 2018;53:49-63.

199. Coronary artery disease in patients with systemic lupus erythematosus. Galindo M, Chung L, Crockett SD, et al. *Nat Clin Pract Rheumatol.* 2005;1:55–59.

200. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Manzi S., Meilahn E.N., Rairie JE, et al. *Am J Epidemiol.* 1997;145:408–415.

201. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. England BR, Thiele GM, Anderson DR, et al. *BMJ.* 2018;361:k1036.

202. Cardiovascular comorbidity in rheumatic diseases: A focus on heart failure. Wright K, Crowson CS, Gabriel SE. *Heart Fail Clin.* 2014;10:339–352.

203. Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis: Hypothesis-generating insights from a cross-sectional study. Toutouzas K, Sfikakis PP, Karanasos A, et al. *Rheumatology.* 2013;52:76–80.

204. Cardiovascular magnetic resonance in autoimmune rheumatic diseases: A clinical consensus document by the European Association of Cardiovascular Imaging. Mavrogeni S, Pepe A, Nijveldt R, et al. *Eur Heart J Cardiovasc Imaging.* 2022 Aug;23(9):e308-22.

205. *Anatomical Studies on the Motion of the Heart and Blood* (1628). William Harvey. Leake translation; Charles Thomas Publisher, Springfield Illinois, 1958.

206. *Galen's System of Physiology and Medicine.* Rudolph E. Siegel publ. S. Karger, Basel, Switzerland. 1968; pp. 30-47.

207. Negative intraventricular diastolic pressure in patients with mitral stenosis: Evidence of left ventricular diastolic suction. Sabbah HN, Anbe DT, Stein PD. *Am J Cardiol.* 1980;45(3):pp 562-66.

208. Left ventricular diastolic suction as a mechanism of ventricular filling. Hori M, Yellin EL, Sonnenblick EH. *Jpn Circ J.*46(1): pp 124-129;1982.

209. The heart as a suction pump. Robinson TF, Factor SM, Sonnenblick EH. *Scientific American.* 254(6): pp 84-91;1986.

210. The heart is not a pump: A refutation of the pressure propulsion premise of heart function. Marinelli R, Fürst B, van der Zee H, McGinn H, Marinelli W. *Frontier Perspectives.* 5(1): pp 15-24;Fall-Winter 1995.

211. Spiral laminar flow in arteries? Stonebridge PA, Brophy CM. *Lancet.* 338(8779): pp 1360-61;1991.

212. Spiral laminar flow in vivo. Stonebridge PA, Hoskins PR, Allan PL, Belck JF. *Clin Sci (Lond).* 91(1): pp 17-21;1996.

213. Helical and retrograde secondary flow patterns in the aortic arch studied by three-directional magnetic resonance velocity mapping. Kilner PJ, Yang GZ, Mohiaddin RH, Firmin DN, Longmore DB. *Circulation.* 88(5): pp 2235-47;1993.

214. Physiological significance of helical flow in the arterial system and its potential clinical applications. Liu X, Sun A, Fan Y, Deng X. *Ann Biomed Engineer.* 43(1): pp 3-15;2015.

215. Three-dimensional blood flow dynamics: spiral/helical laminar flow. Stonebridge PA. *Methodist Debakey Cardiovasc J.* 2011;7(1):21-26.

216. Spiral laminar flow: a survey of a three-dimensional arterial flow pattern in a group of volunteers. Stonebridge PA, Suttie SA, Ross R, Dick J. *Eur J Vasc Endovasc Surg.* 2016;52(5):674-80.

217. Patterns of flow in the left coronary artery. Sabbah HN, Walburn FJ, Stein PD. *J Biomech Engin.* 1984;106(3):272-79.

218. Flow visualization study of spiral flow in the aorta-renal bifurcation. Fulker D, Javadzadegan A, Li Z, Barber T. *Comput Meth Biomech Biomed Engin.* 2017;20(13):1438-41.

219. The mechanics of spiral flow: Enhanced washout and transport. Huang Zhang P, Tkatch C, Newman R, Grimme W, et al. *Artif Organs.* 2019;43(12):1144-53.

220. Parallel and spiral flow patterns of vertebral artery contributions to the basilar artery. Smith AS, Belton JR. *Am J Neuroradiol.* 1995;16(8):272-79.

221. Flow patterns in the human carotid artery bifurcation. Motomiya M, Karino T. *Stroke.* 1984;15(1):50-56.

222. Spiral systolic blood flow in the ascending aorta and aortic arch analyzed by echodynamography. Tanaka M, Sakamoto T, Sugawara S, Nakajima H, et al. *J Cardiol.* 2010;56(1): 97-110.

223. Flow patterns in dog aortic arch under a steady flow condition simulating mid-systole. Endo S, Sohara Y, Karino T. *Heart Vessels.* 1996;11(4):180-91.

224. Blood flow analysis of the aortic arch using computational fluid dynamics. Numata S, Itatani K, Kanda K, Doi K, et al. *Eur J Cardiothorac Surg.* 2016;49(6):1578-85.

225. Aether, fields & energy dynamics in living bodies - Part I. Thorp KE, Thorp JA, Walker PR. *G Med Sci.* 2021;2(5):014-025.

226. Aether, fields & energy dynamics in living bodies - Part II. Thorp KE, Thorp JA, Walker PR. *G Med Sci.* 2021;2(6):001-020.

227. Aether, fields & energy dynamics in living bodies - Part III. Thorp KE, Thorp JA, Walker PR. *G Med Sci.* 2021;2(6):021-047.

228. Diastolic Dysfunction. Little WC, Cheng CP. *Cardiol Rev.* 6(4): pp 231-239;1988.

229. State of the art: 'Diastology' research 1998. Oki T. *J Med Invest.* 45(1-4): pp 9-25;1998.

230. Cardiac syndrome X – the present knowledge. Piegza M, Wierzba D, Piezga J. *Psychiatr Pol.* 2021 Apr;55(2):363-75.

231. Cardiac syndrome X: Update. Agrawal S, Mehta PK, Bairey Merz CN. *Heart Fail Clin.* 2016 Jan;12(1):141-56.

232. Role of inflammation and endothelial dysfunction in the pathogenesis of cardiac syndrome X. Gil-Ortega I, Marzoa Rivas R, Rios Vazquez R, Kaski JC. *Future Cardiol.* 2006 Jan;2(1):63-73.

233. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. *JACC Cardiovasc Imaging.* 2013 Jun;6(6):660-67.

234. Coronary microvascular dysfunction. Vancheri F, Longo G, Vancheri S, et al. *J Clin Med.* 2020 Sep;9(9):288.

235. Small-Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. Berry C, Sidik N, Pereira A.C, Ford TJ, et al. *J Am Heart Assoc.* 2019;8:e011104.

236. Cerebral Small Vessel Disease and Risk of Death, Ischemic Stroke, and Cardiac Complications in Patients With Atherosclerotic Disease. Conijn MMA, Kloppenborg RP, Algra A, et al. *Stroke.* 2011;42:3105–3109.

237. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Pantoni L. *Lancet Neurol.* 2010;9:689–701.

238. Inflammation and cerebral small vessel disease: A systematic review. Low A, Mak E, Rowe JB, et al. *Ageing Res Rev.* 2019 Aug:53:100916.

239. The waveform index of the ophthalmic artery predicts impaired coronary flow reserve. Kojima S, Maruyoshi H, Kojima S, Ogawa H. *Microvasc Res.* 2016 May;105:30-33.

240. Inflammation in Coronary Microvascular Dysfunction. Sagris M, Theofilis P, Antnopoulos AS, et al. *Int J Mol Sci.* 2021 Dec;22(24):13471.

241. Inflammatory markers for arterial stiffness in cardiovascular diseases. Mozos I, Malainer C, Horbańczuk J, et al. *Front Immunol.* 2017 Aug;8:1058.

242. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. van Bussel BC, Schouten F, Henry RM, et al. *Hypertension.* 2011 Oct;58(4):588-95.

243. Coronary Microvascular Dysfunction Identifies Patients at High Risk of Adverse Events Across Cardiometabolic Diseases. Osborne MT, Bajaj NS, Taqueti VR, et al. *J Am Coll Cardiol.* 2017 Dec;70(22):2835-37.

244. Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation. Mehta SK, Rame JE, Khera A, et al. *Hypertension.* 2007 Jun;49(6):1385–91.

245. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Petrie JR, Guzik TJ, Touyz RM. *Can J Cardiol.* 2018 May;34(5):575-84.

246. Obesity and hypertension. Seravalle G, Grassi G. *Pharmacol Res.* 2017 Aug;122:1-7.

247. Microvascular endothelial dysfunction in obesity and hypertension. Virdis A, Neves MF, Duranti E, et al. *Curr Pharm Des.* 2013;19(13):2382-89.

248. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Petrie JR, Guzik TJ, Touyz RM. *Can J Cardiol.* 2018 May;34(5):575-84.

249. Obesity and hypertension. Seravalle G, Grassi G. *Pharmacol Res.* 2017 Aug;122:1-7.

250. Microvascular endothelial dysfunction in obesity and hypertension. Virdis A, Neves MF, Duranti E, et al. *Curr Pharm Des.* 2013;19(13):2382-89.

251. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Zanatta E, Colombo C, D'Amico G, et al. *Int J Mol Sci.* 2019 Nov;20(22):5563.

252. Rheumatoid arthritis: an autoimmune disease with female preponderance and cardiovascular risk equivalent to diabetes mellitus: Role of magnetic resonance. Mavrogeni S, Dimitroulas T, Bucciarelli-Ducci C, et al. *Inflamm Allergy Drug Targets.* 2014;13(2):81-93.

253. Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. DeMizio DJ, Geraldino-Pardilla LB. *Rheumatol Ther.* 2020 Mar;7(1):19-33.

254. Early myocardial changes in patients with rheumatoid arthritis without known cardiovascular diseases—A comprehensive cardiac magnetic resonance study. Malczuk E, Tłustochowicz W, Kramarz E, et al. *Diagnostics (Basel).* 2021 Dec;11(12):2290.

255. Is there a brain/heart interaction in rheumatoid arthritis and seronegative spondyloarthropathies? A combined brain/heart magnetic resonance imaging reveals the answer. Markousis-Mavrogenis G, Koutsogeorgopoulou L, Dimitroulas T, et al. *Curr Rheumatol Rep.* 2020 Jun;22(8):39.

256. Prevalence and associatons of hypertension and its control in patients with rheumatoid arthritis. Panoulas VF, Douglas KMJ, Millionis HJ, et al. *Rheumatology (Oxford).* 2007 Sep;46(9):1477-82.

257. Endothelial dysfunction in patients with rheumatoid arthritis: The role of hypertension. Anyfanti P, Gavriilaki E, Douma S, et al. *Curr Hypertens Rep.* 2020 Jul;22(8):56.

258. Risk factors for hypertension in rheumatoid arthritis patients—a systematic review. Hadwen B, Stranges S, Barra L. *Autoimmun Rev.* 2021 Apr;20(4):102786.

259. Inflammation and hypertension in rheumatoid arthritis. Manavathongchai S, Bian A, Rho YH, et al. *J Rheumatol.* 2013 Nov;40(11):1806-11.

260. The prevalence of comorbidity in rheumatoid arthritis: a systematic review and meta-analysis. Hill J, Harrison J, Christian D, et al. *Br J Community Nurs.* 2022 May;27(5):232-41.

261. Inflammatory markers in patients with rheumatoid arthritis. Shrivastava AK, Singh HV, Raizada A, et al. *Allergol Immunopathol (Madr).* 2015 Jan;43(1):81-87.

262. Elevated levels of inflammatory markers in women with rheumatoid arthritis. Costa CM, Santos MATD, Pernambuco AP. *J Immunoassay Immunochem.* 2019;40(5):540-54.

263. Myocardial Microvascular Dysfunction in Rheumatoid Arthritis. Amigues I, Russo C, Giles JT, et al. *Circ Cardiovasc Imaging.* 2019;12:e007495.

264. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Atzeni F, Sarzi-Puttini P, De Blasio G, et al. *Ann NY Acad Sci.* 2007 Jun;1108:392-97.

265. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Ciftci O, Yilmaz S, Topcu S, et al. *Atherosclerosis.* 2008;198:332–337.

266. Impaired coronary vasodilator reserve and adverse prognosis in patients with systemic inflammatory disorders. Weber BN, Stevens E, Perez-Chada LM, et al. *JACC Cardiovasc Imaging.* 2021 Nov;14(11):2212-2220.

267. Prospective changes in diastolic function in patients with rheumatoid arthritis. Park E, Ito K, Iqbal R, et al. *Arthritis Res Ther.* 2022 Aug; 24(1):184.

268. Diastolic dysfunction in rheumatoid arthritis: A usual travel mate? Cavazzana I, Vizzardi E, Franceschini F. *Monaldi Arch Chest Dis.* 2019 Sep; 89(3).

269. Incidence and predictors of new onset diastolic dysfunction in asymptomatic patients with rheumatoid arthritis without overt cardiac disease. Dal Piaz EC, Cioffi G, Ognibeni F, et al. *Monaldi Arch Chest Dis.* 2019 Sep;89(3).

270. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Liang KP, Myasoedova E, Crowson CS, et al. *Ann Rheum Dis.* 2010 Sep;69(9):1665-70.

271. Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis. Kim GH, Park YJ. *Arthritis Res Ther.* 2021 Sep; 23(1):247.

272. Diastolic dysfunction abnormalities in rheumatoid arthritis: Relation with duration of disease. Udayakumar N, Venkatesan S, Rajendiran C. *Singapore Med J.* 2007 Jun;48(6):537-42.

273. Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis: Hypothesis-generating insights from a cross-sectional study. Toutouzas K, Sfikakis PP, Karanasos A, et al. *Rheumatology.* 2013;52:76–80.

274. Risk factors for asymptomatic ventricular dysfunction in rheumatoid arthritis patients. Garza-García C, Rocío SS, Orea-Tejeda A, et al. *ISRN Cardiol.* 2013 Dec;2013:635439.

275. Early diagnosis of subclinical left ventricular dysfunction in postmenopausal women with rheumatoid arthritis. Maiello M, Cecere A, Ciccone MM, et al. *Clin Physiol Funct Imaging.* 2023 Apr.

276. Prevalence of left ventricular dysfunction in rheumatoid arthritis. Renjith AS, Marwaha V, Aggarwal N, et al. *J Fam Med Prim Care.* 2017 Jul;6(3):622-26.

277. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Rexhepaj N, Bajraktari G, Berisha I, et al. *Int J Clin Pract.* 2006 Jun;60(6):683-68.

278. Combined circumferential and longitudinal left ventricular systolic dysfunction in patients with rheumatoid arthritis without overt cardiac disease. Cioffi G, Viapiana O, Ognibeni F, et al. *J Am Soc Echocardiogr.* 2016 Jul;29(7):689-98.

279. Prevalence and factors associated with subclinical left ventricular systolic dysfunction evaluated by mid-wall mechanics in rheumatoid arthritis. Cioffi G, Viapiana O, Ognibeni F, et al. *Echocardiography.* 2016 Sep;33(9):1290-99.

280. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Recio-Mayoral A, Mason JC, Kaski JC, et al. *Eur Heart J.* 2009;30:1837–1843.

281. Coronary artery disease in patients with systemic lupus erythematosus. Galindo M, Chung L, Crockett SD, et al. *Nat Clin Pract Rheumatol.* 2005;1:55–59.

282. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Manzi S., Meilahn E.N., Rairie JE, et al. *Am J Epidemiol.* 1997;145:408–415.

283. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Hirata K, Kadirvelu A, Kinjo M, et al. *Arthritis Rheum.* 2007;56:1904–1909.

284. Association between serum total antioxidant status and coronary microvascular functions in patients with SLE. Yılmaz S, Caliskan M, Kulaksızoglu S, et al. *Echocardiography.* 2012;29:1218–1223.

285. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. Ishimori ML, Martin R, Berman DS, et al. *JACC Cardiovasc Imaging.* 2011;4:27–33.

286. Early Detection of Silent Myocardial Impairment in Drug-Naive Patients with New-Onset Systemic Lupus Erythematosus: A Three-Center Prospective Study. Guo Q, Wu LM, Wang Z, et al. *Arthritis Rheumatol.* 2018;70:2014–2024.

287. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Puntmann VO, D'Cruz D, Smith Z, et al. *Circ Cardiovasc Imaging.* 2013 Mar;6(2):295-301.

288. Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, et al. *Lupus.* 2018 Apr;27(4):564-71.

289. A Five-Year Follow up of Coronary Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort. Sandhu VK, Wei J, Thomson LEJ, et al. *Arthritis Care Res.* 2020 Jul;72(7):882-87.

290. High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus. Winau L, Hinojar Baydes R, Braner A, et al. *Ann Rheum Dis.* 2018;77:1590–1598.

291. Systemic sclerosis: Recent insight in clinical management. Zanatta E, Codullo V, Avouac J, et al. *Jt Bone Spine.* 2020 Jul;87(4):293-99.

292. Scleroderma epidemiology update. Calderon LM, Pope JE. *Curr Opin Rheumatol.* 2021 Mar;33(2):122-27.

293. Scleroderma with an update about clinic-pathological correlation. Rongioletti F, Ferreli C, Atzori L, et al. *G Ital Dermatol Venereol.* 2018 Apr;153(2):208-15.

294. Primary myocardial involvement in systemic sclerosis: Evidence for a microvascular origin. Allanore Y, Meune C. *Clin. Exp. Rheumatol.* 2010;28:S48–S53.

295. Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Montisci R, Vacca A, Garau P, et al. *Ann Rheum Dis.* 2003;62:890–893.

296. Absence of epicardial coronary stenosis in patients with systemic sclerosis with severe impairment of coronary flow reserve. Vacca A, Siotto P, Cauli A, et al. *Ann Rheum Dis.* 2006;65:274–275.

297. Blunted coronary flow reserve in systemic sclerosis. Sulli A., Ghio M., Bezante GP, et al. *Rheumatology.* 2004;43:505–509.

298. Coronary microvascular dysfunction in asymptomatic patients affected by systemic sclerosis—Limited vs. diffuse form. Sulli A, Ghio M, Bezante L, et al. *Circ J.* 2015;79:825–829.

299. Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association. Zanatta E, Famoso G, Boscain F, et al. *Autoimmun Rev.* 2019;18:177–183.

300. Cardiac magnetic resonance imaging in systemic sclerosis: A cross-sectional observational study of 52 patients. Hachulla AL, Launay D, Gaxotte V, et al. *Ann Rheum Dis.* 2009 Dec;68(12):1878-84.

301. Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. Rodríguez-Reyna TS, Morelos-Guzman M, Hernández-Reyes P, et al. *Rheumatology.* 2015;54:647–65.

302. Raynaud's phenomenon. Haque A, Hughes M. *Clin Med (Lond).* 2020 Nov;580-87.

303. Raynaud's phenomenon. Herrick AL, Wigley FM. *Best Pract Res Clin Rheumatol.* 2020 Feb;34(1):101474.

304. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis. Lekakis J, Mavrikakis M, Emmanuel M, et al. *Clin Exp Rheumatol.* 1998 Mar;16(2):135-40.

305. Reversible myocardial perfusion defects during cold challenge in scleroderma. Long A, Duffy G, Bresnihan B. *Br. J. Rheumatol.* 1986;25:158–161.

306. Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. Mizuno R, Fujimoto S, Saito Y, et al. *Eur J Heart Fail.* 2010;12:268–275.

307. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Alexander EL, Firestein GS, Weiss JL, et al. *Ann Int Med.* 1986 Nov;105(5):661-68.

308. Abnormal retinal microvasculature found in active rheumatoid arthritis: A different perspective of microvascular health. Babaoğlu H, Baytaroğlu A, Torğutalp M, et al. *Turk J Med Sci.*
2019 Feb;49(1):20-26.

309. Retinal vessel morphology in rheumatoid arthritis: association with systemic inflammation, subclinical atherosclerosis, and cardiovascular risk. Anyfanti P, Triantafyllou A, Gkaliagkousi E, et al. *Microcirculation.* 2017 Nov;24(8).

310. Retinal microangiopathy in systemic lupus erythematosus. Santos R, Barojas E, Alarcón-Segovia D, et al. *Am J Ophthalmol.* 1975 Aug;80(2):249-52.

311. Involvement of the eye in SLE and scleroderma. A study using fluorescein angiography in addition to clinical ophthalmic assessment. Grennan DM, Forrester J. *Ann Rheum Dis.*
1977 Apr;36(2):152-56.

312. Subclinical retinal capillary abnormalities in juvenile systemic lupus erythematosus without ocular involvement. Yılmaz Tuğan B, Sönmez HE, Yüksel N, et al. *Ocul Immunol Inflamm.*
2023 Apr; 31(3):576-84.

313. Analysis of foveal microvascular abnormalities in patients with systemic lupus erythematosus using optical coherence tomography angiography. An Q, Gao J, Liu L, et al. *Ocul Immunol Inflamm.* 2021 Nov;29(7-8):1392-97.

314. Retinal microcirculation abnormalities in patients with systemic sclerosis: An explorative optical coherence tomography angiography study. Carnevali A, Giannaccare G, Gatti V, et al. *Rheumatology (Oxford).* 2021 Dec;60(12):5827-32.

315. Retinal findings in systemic sclerosis: A comparison of nailfold capillaroscopic patterns. Ushiyama O, Ushiyama K, Yamada T, et al. *Ann Rheum Dis.* 2003 Mar;62(3):204-07.

316. Retinal and choriocapillary vascular changes in early stages of multiple sclerosis: A prospective study. Montorio D, Lanzillo R, Carotenuto A, et al. *J Clin Med.* 2021 Dec;10(24):5756.

317. Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. Lanzillo R, Cennamo G, Criscuolo C, et al. *Mult Scler.* 24(13):1706.

318. Retinal circulatory abnormalities in type 1 diabetes. Feke GT, Buzney SM, Ogasawara H, et al. *Invest Ophthalmol Vis Sci.* 1994 Jun;35(7):2968-75.

319. Retinal vascular reactivity in type 1 diabetes patients without retinopathy using optical coherence tomography angiography. Sousa DC, Leal I, Moreira S, et al. *Invest Ophthalmol Vis Sci.*
2020 Jun; 61(6):49.

320. Retinal vascular abnormalities in persons with type 1 diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVIII. Klein R, Klein BEK, Moss SE, et al. *Ophthalmology.* 2003 Nov;110(11):211825.

321. Retinal vasculitis revealed by fluorescein angiography in patients with inflammatory bowel disease. Matsuo T, Yamaoka A. *Jpn J Ophthalmol.* 1998 Sep;42(5):398-400.

322. Frequency of ophthalmological posterior segment findings in patients with inflammatory bowel disease. Nakayama LF, Bergamo VC, Conti ML, et al. *Arq Gastroenterol.* 2018 Apr;55(2):188-91.

323. Evidence of microvascular changes in the retina following Kawasaki disease. Chen KY, Burgner DP, Wong TY, et al. *Sci Rep.* 2017 Jan;7:40513.

324. Evidence for the detection of subclinical retinal involvement in systemic lupus erythematosus and Sjögren's syndrome: A potential association with therapies. Conigliaro P, Triggianese P, Draghessi G, et al. *Arch Allergy Immunol.* 2018;177(1):45-56.

325. Reduced retinal microvascular density related to activity status and serum antibodies in patients with Graves' ophthalmopathy. Wu Y, Tu Y, Bao L, et al. *Curr Eye Res.* 2020 May;45(5):576-84.

326. Heart rate variability in the prediction of mortality: A systematic review and meta-analysis of healthy and patient populations. Jarczok MN, Weimer K, Braun C, et al. *Neurosci Biobehav Rev.* 2022 Dec;143:104907.

327. Heart rate variability: Origins, methods, and interpretive caveats. Berntson GG, Bigger JT Jr, Eckberg DL, et al. *Psychophysiology.* 1997 Nov;34(6):623-48.

328. Heart rate variability: A review. Rajendra AU, Paul JK, Kannathal N, et al. *Med Biol Eng Comput.* 2006 Dec;44(12):1031-51.

329. Heart rate variability. Frequency domain analysis. Ori Z, Monir G, Weiss J, et al. *Cardiol Clin.* 1992 Aug;10(3):499-537.

330. Heart rate variability. Cygankiewicz I, Zareba W. *Handb Clin Neurol.* 2013;117:379-93.

331. Heart rate variability (HRV), predicts outcomes in COVID-19. Mol MBA, Strous MTA, van Osch FHM, et al. *PLoS One.* 2021 Oct;16(10):e0258841.

332. Decreased heart rate variability in COVID-19. Yin C, Li J, Wang Z, Zhi Y, Xu L. *Intensive Care Res.* 2023;3(1):87-91.

333. Cardiovascular dynamics in COVID-19: A heart rate variability investigation. Aliani C, Rossi E, Luchini M, et al. *Annu Int Conf IEEE Eng Med Biol Sci.* 2022 Jul;2022:2278-81.

334. Characterization of cardiac autonomic function in COVID-19 using heart rate variability: A hospital based preliminary observational study. Kaliyaperumal D, Rk K, Alagesan M, et al. *Basic Clin Physiol Pharmacol.* 2021 Mar;32(3):247-53.

335. Heart rate variability and cardiac autonomic functions in post-COVID period. Asarcikli LD, Hayiroglu Mİ, Osken A, et al. *Interv Card Electrophysiol.* 2022 Apr;63(3):715-21.

336. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Aranyó J, Bazan V, Lladós G et al. *Sci Rep.* 2022 Jan;12(1):298.

337. Automatic COVID-19 severity assessment from HRV. Aliani C, Rossi E, Luchini M, et al. *Sci Rep.* 2023 Jan;13(1):1713.

338. *The Integrative Action of the Nervous System.* Charles S Sherrington. Publ. Charles Scribner's Sons. 1906.

339. The autonomic nervous system. Langley JN. *Brain.* 1903;26(1):1-26.

340. *Neurocardiology* eds. J. Andrew Armour & Jeffrey L. Ardell Oxford University Press. 1994.

341. Autonomic function and rheumatoid arthritis: A systematic review. Adlan AM, Lip GY, Paton JF, et al. *Semin Arthritis Rheum.* 2014 Dec;44(3):283-304.

342. Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. Adlan AM, Paton JF, Lip GY, et al. *J Physiol.* 2017 Feb;595(3):967-81.

343. Heart rate variability in patients with rheumatoid arthritis. Evrengül H, Dursonoglu D, Cobankara V, et al. *Rheumatol Int.* 2004 Jul;24(4):198-202.

344. Evaluation of cardiac autonomic functions in patients with systemic lupus erythematosus. Yorgun H, Canpolat U, Aytemir K, et al. *Lupus.* 2012 Apr;21(4):373-79.

345. Heart rate variability in juvenile systemic lupus erythematosus patients. Başaran Ö, Çetin İİ, Aydın F, et al. *Turk J Pediatr.* 2019;61(5):733-40.

346. Heart rate variability in patients with systemic lupus erythematosus: A systematic review and methodological considerations. *Lupus.* 2018 Jul;27(8):1225-39.

347. Sympatho-vagal dysfunction in systemic sclerosis: A follow-up study. Rodrigues GD, Carandina A, Scatà C, et al. *Life (Basel).* 2022 Dec;13(1):34.

348. Autonomic dysfunction in systemic sclerosis: Time and frequency domain 24 hour heart rate variability analysis. Ferri C, Emdin M, Giuggioli D, et al. *Br J Rheumatol.* 1997 Jun;36(6):669-76.

349. Twenty-four hour heart period variability in systemic sclerosis. Morelli S, Piccirillo G, Fimognari F, et al. *J Rheumatol.* 1996 Apr;23(4):643-45.

350. Heart rate variability analysis in patients with multiple sclerosis. Damla O, Altug C, Pinar KK, et al. *Mult Scler Relat Disord.* 2018 Aug;24:64-68.

351. Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage. Videira G, Castro P, Vieira B, et al. *J Neurol Sci.* 2016 Aug;367:133-37.

352. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Flachenecker P, Reiners K, Krauser M, et al. *Mult Scler.* 2001 Oct;7(5):327-34.

353. Heart rate variability and baroreflex sensitivity abnormalities in Guillain-Barré syndrome: A pilot study. Tan CY, Shahrizaila N, Yeoh K, et al. *Clin Auton Res.* 2019 Jun;29(3):339-48.

354. Cardiovascular autonomic assessment in Guillain-Barré syndrome: A longitudinal study. Tan CY, Shahrizaila N, Tan HT, et al. *Neurol India.* 2022 Sep;70(5):1856-59.

355. Decreased heart rate variability in patients with psoriatic arthritis. Gaydukova I, Rebrov A, Nikitina N, et al. *Clin Rheumatol.* 2012 Sep;31(9):1377-81.

356. Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis. Novikova DS, Korotaeva TV, Loginova E, et al. *Ter Arkh.* 2009;81(6):47-52.

357. Heart rate variability and inflammatory bowel disease in humans: A systematic review and meta-analysis. Kim KN, Yao Y, Ju SY. *Medicine (Baltimore).* 2020 Nov;99(48):e23430.

358. Heart rate variability as a predictor of disease exacerbation in pediatric inflammatory bowel disease. Yerushalmy-Feler A, Cohen S, Lubetzky R, et al. *Psychosom Res.* 2022 Jul;158:110911.

359. Cardiac and autonomic function in patients with Crohn's disease during remission. Zawadka-Kunikowska M, Słomko J, Kłopocka M, et al. *Adv Med Sci.* 2018 Sep;63(2):334-40.

360. Heart rate variability in patients with Sjögren's syndrome. Tumiati B, Perazzoli F, Negro A, et al. *Clin Rheumatol.* 2000;19(6):477-80.

361. Spectral analysis of heart rate and blood pressure variability in primary Sjögren's syndrome. Barendregt PJ, Tulen JH, van den Meiracker AH, et al. *Ann Rheum Dis.* 2002 Mar;61(3):232-36.

362. Autonomic nervous system dysfunction in primary Sjögren's syndrome. Davies K, Ng WF. *Front Immunol.* 2021 Jul;12:702505.

363. Heart rate variability in adolescents and adults with type 1 diabetes. Faulkner MS, Hathaway DK, Milstead EJ, et al. *Nurs Res.* 2001 Mar;50(2):95-104.

364. Heart rate variability and heart rate recovery in patients with type 1 diabetes mellitus. Turker Y, Aslantas Y, Aydin Y, et al. *Acta Cardiol.* 2013 Apr;68(2):145-50.

365. Heart rate variability in children with type 1 diabetes mellitus. Gardim CB, de Oliveira BA, Bernardo AF, et al. *Rev Paul Pediatr.* 2014 Jun;32(2):279-85.

366. Assessment of autonomic nervous system function in patients with Behçet's disease by spectral analysis of heart rate variability. Aksöyek S, Aytemir K, Ozer N, et al. *J Auton Nerv Syst.* 1999 Sep;77(2-3):190-94.

367. Heart rate variability as an indicator of autonomic nervous system disturbance in Behçet's disease. Ben Mrad I, Ben Mrad M, Besbes B, et al. *J Gen Med.* 2021 Aug;14:4877-86.

368. Cardiac autonomic regulation is disturbed in children with euthyroid Hashimoto thyroiditis. Kilic A, Gulgun M, Tascilar ME, et al. *Tohoku J Exp Med.* 2012 Mar;226(3):191-95.

369. Decreased heart rated variability in appropriate sinus tachycardia and effects of rapid rate. Castellanos A, Lopera G, Moleiro F, et al. *Am J Cardiol.* 1999 Nov;84(10):1264-66.

370. Effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension: Analysis of Kailuan follow-up study. Zhao MX, Zhao Q, Zheng M, et al. *BMJ Open.* 2020 Mar;10(3):e032699.

371. Elevated heart rate as a predictor of increased cardiovascular morbidity. Palatini P. *J Hypertens Suppl.* 1999 Aug;17(3):S3-10.

372. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Grassi G, Arenare F, Quarti-Trevano F, et al. *Prog Cardiovasc Dis.* 2009 Jul;52(1):31-37.

373. Reduced heart rate variability in hypertension: Associations with lifestyle factors and plasma renin activity. Virtanen R, Jula A, Kuusela T, et al. *J Hum Hypertension.* 2003. Mar;17(3):171-79.

374. Association of arterial stiffness with all-cause and cause-specific mortality in the diabetic population: A national cohort study. Liu C, Pan H, Kong F, et al. *Front Endocrinol (Lausanne).* 2023 Mar;14:1145914.

375. Relationship between reduced heart rate variability and increased arterial stiffness evaluated by the cardio-ankle vascular index in people with type 2 diabetes. Kase M, Iijima T, Niitani T, et al. *Diabetol Int.* 2022 Sep;14(1):94-102.

376. Aortic stiffness: a major risk factor for multimorbidity in the elderly. Triposkiadis F, Xanthopoulos A, Lampropoulos K, et al. *J Clin Med.* 2023 Mar;12(6):2321.

377. Pulse pressure, arterial compliance and cardiovascular morbidity and mortality. Jia G, Aroor AR, Sowers JR. *Curr Opin Nephrol Hypertens.* 1999 May;8(3):335-42.

378. Sympathetic neural modulation of arterial stiffness in humans. Nardone M, Floras JS, Millar PJ. *Am J Physiol Heart Circ Physiol.* 2020 Dec;319(6):H1338-46.

379. Inflammation and arterial stiffness in humans. Jain S, Khera R, Corrales-Medina VF, et al. *Atherosclerosis.* 2014 Dec;237(2):381-90.

380. Arterial stiffness: A nexus between cardiac and renal disease. Jia G, Aroor AR, Sowers JR. *Cardiorenal Med.* 2014 Apr;4(1):60-71.

381. Elevated muscle sympathetic nerve activity contributes to central artery stiffness in young and middle-age/older adults. Holwerda SW, Luehrs RE, DuBose L, et al. *Hypertension.* 2019 May;73(5):1025-35.

382. Heart rate variability and inflammation: a meta-analysis of human studies. Williams DP, Koenig J, Carnevali L, et al. *Brain Behav Immun.* 2019 Aug;80:219-226.

383. The relationship between heart rate variability and inflammatory markers in cardiovascular disease. Haensel A, Mills PJ, Nelesen RA, et al. *Psychoneuroendocrinol.* 2008 Nov;33(10):1305-12.

384. Heart rate variability predicts levels of inflammatory markers: Evidence for the vagal inflammatory pathway. Cooper TM, McKinley PS, Seeman TE, et al. *Brain Behav Immun.* 2015 Oct; 49:94-100.

385. Lower heart rate variability predicts increased level of C-reactive protein four years later in healthy, non-smoking adults. Jarczok MN, Koenig J, Mauss D, et al. *J Intern Med.* 2014 Dec;276(6):667-71.

386. Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: The Cardiovascular Health Study. Stein PK, Barzilay JI, Chaves PH, et al. *J Am Geriatr Soc.* 2008 Feb;56(2):315-21.

387. Heart rate variability and biomarkers of systemic inflammation in patients with stable coronary artery disease: Findings from the Heart and Soul Study. von Känel R, Carney RM, Zhao S, et al. *Clin Res Cardiol.* 2011 Mar;100(3):241-47.

388. Microvascular dysfunction as a link between obesity, insulin resistance and hypertension. Karaca Ü, Schram MT, Houben AJ, et al. *Diabetes Res Clin Pract.* 2014 Mar;103(3):382-87.

389. Microvascular endothelial dysfunction in obesity and hypertension. Virdis A, Neves MF, Duranti E, et al. *Curr Pharm Des.* 2013;19(13):2382-89.

390. Diabetes, hypertension and cardiovascular disease: Clinical insights and vascular mechanisms. Petrie JR, Guzik TJ, Touyz RM. *Can J Cardiol.* 2018 May;34(5):575-84.

391. Microvascular dysfunction: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. De Boer MP, Meijer RI, Wijnstok NJ, et al. *Microcirculation.* 2012 Jan;19(1):5-18.

392. Microvascular dysfunction in diabetes mellitus and cardiometabolic disease. Horton WB, Barrett EJ. *Endocrinol Rev.* 2021 Jan;42(1):29-55.

393. Autonomic control of ventricular function in health and disease: Current state of the art. van Weperen VYH, Ripplinger CM, Vaseghi M. *Clin Auton Res.* 2023 May:1-27.

394. Heart rate variability: A non-invasive electrocardiographic method to measure the autonomic nervous system. Sztajzel J. *Swiss Med Weekly.* 2004 Sep;34(35-36):514-22.

395. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases. Stojanovich L, Milovanovich B, de Luka SR, et al. *Lupus.* 2007;16(3):181-85.

396. On heart rate variability and autonomic activity in homeostasis and in systemic inflammation. Scheff JD, Griffel B, Corbett SA, et al. *Math Biosci.* 2014 Jun;252:36-44.

397. The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. Bellocchi C, Carandina A, Montinaro B, et al. *Int J Mol Sci.* 2022 Feb;23(5):2449.

398. Impaired heart rate variability as a marker of cardiovascular autonomic dysfunction in multiple sclerosis. Tombul T, Anlar O, Tuncer M, et al. *Acta Neurol Belg.* 2011 Jun;111(2):116-20.

399. Cardiac autonomic neuropathy in type 1 and 2 diabetes: Epidemiology, pathophysiology, and management. Williams S, Raheim SA, Khan MI, et al. *Clin Ther.* 2022 Oct;44(10):1394-1416.

400. Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. Bonaz B, Sinniger V, Pellissier S. *J Physiol.* 2016 Oct;594(20):5781-90.

401. Evidence of reduced parasympathetic autonomic regulation in inflammatory joint disease: A meta-analysis study. Provan SA, Olstad DS, Solberg EE, et al. *Semin Arthritis Rheum.* 2018 Aug; 48(1):134-40.

402. Vagal tone and the inflammatory reflex. Thayer JF. *Cleve Clin J Med.* 2009 Apr;76 Suppl:S23-26.

403. Vagal influences in rheumatoid arthritis. Rasmussen SE, Pfeiffer-Jensen M, Drewes AM, et al. *Scand J Rheumatol.* 2018 Jan;47(1):1-11.

404. Association of vagal tone with serum insulin, glucose, and diabetes mellitus—The ARIC Study. Liao D, Cai J, Brancati FL, et al. *Diabetes Res Clin Pract.* 1995 Dec;30(3):211-21.

405. Parasympathetic nervous system dysfunction in primary Sjögren's syndrome. Hocevar A, Tomsic M, Praprotnik S, et al. *Ann Rheum Dis.* 2003 Aug;62(8):702-04.

406. Heart rate fluctuations in diabetic patients with cardiac vagal dysfunction: A spectral analysis. Weise F, Heydenreich F, Runge U. *Diabet Med.* 1988 May;5(4):324-27.

407. Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. Koopman FA, van Maanen MA, Vervoordeldonk MJ, et al. *J Intern Med.* 2017 Jul;282(1):64-75.

408. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. Huston JM, Tracey KJ. *J Intern Med.* 2011 Jan;269(1):45-63.

409. The cholinergic anti-inflammatory pathway: a critical review. Martelli D, McKinley MJ, McAllen RM. *Auton Neurosci.* 2014 May;182:65-69.

410. Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis? Koopman FA, Schuurman PR, Vervoordeldonk MJ, et al. *Best Pract Res Clin Rheumatol.* 2014 Aug;28(4):625-35.

411. Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: Results of a pilot study. Drewes AM, Brock C, Rasmussen SE, et al. *Scand J Rheumatol.* 2021 Jan;50(1):20-27.

412. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn's disease. Sinniger V, Pellissier S, Fauvelle F, et al. *Neurogastroenterol Motil.* 2020 Oct;32(10):e13911.

413. Transcutaneous cervical vagal nerve stimulation modulates cardiac vagal tone and tumor necrosis factor-alpha. Brock C, Brock B, Aziz Q, et al. *Neurogastroenterol Motil.* 2017 May;29(5).

414. Is there a place for vagal nerve stimulation in inflammatory bowel diseases? Bonaz B. *Bioelectron Med.* 2018 Apr;4:4.

415. Inflammatory bowel disease: role of vagal nerve stimulation. Fornaro R, Actis GC, Caviglia GP, et al. *J Clin Med.* 2022 Sep;11(19):5690.

416. Vagus nerve stimulation as a novel treatment for systemic lupus erythematosus: Study protocol for a randomized, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study. Zinglersen AH, Drange IL, Myhr KA, et al. *BMJ Open.* 2022 Sep; 12(9):e064552.

417. The effect of transcutaneous vagus nerve stimulation in patients with polymyalgia rheumatica. Venborg J, Wegeberg AM, Kristensen S, et al. *Pharmaceuticals (Basel).* 2021 Nov;14(11):1166.

418. Vagal nerve stimulation-modulation of the anti-inflammatory response and clinical outcome in psoriatic arthritis or ankylosing spondylitis. Brock C, Rasmussen SE, Drewes AM, et al. *Mediators Inflamm.* 2021 May;2021:9933532.

419. The vagus nerve in the neuro-immune axis: Implications in the pathology of the gastrointestinal tract. Bonaz B, Sinniger V, Pellissier S. *Front Immunol.* 2017 Nov;8:1452.

420. Energy dynamics in dementia & the neurodegenerative diseases: a new causal paradigm. Thorp KE, Thorp JA, Northrup C, et al. *G Med Sci.* 2023;4(1):348-405.

421. *Species and Specificity: An Interpretation of the History of Immunology.* Pauline M H Mazumdar. Cambridge University Press. 1995.

422. The Birth of Immunology: I. Metchnikoff, the Embryologist. Chernyak L, Tauber AI. *Cell Immunol.* 1988;117:218-233.

423. The Birth of Immunology: II. Metchnikoff and His Critics. Tauber AI, Chernyak L. *Cell Immunol.* 1989;121:447-473.

424. The Birth of Immunology: III. The Fate of the Phagocytosis Theory. Tauber AI. *Cell Immunol* 1992;139:505-530.

425. *A History of Immunology.* Arthur M. Silverstein. publ Academic Press, Inc. 1989.

426. Travels and travails of autoimmunity: A historical journey from discovery to rediscovery. Mackay IR. *Autoimmunity Rev.* 2010;A251–A258.

427. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. *J Lab Clin Med.* 38(1):1-10.

428. Autoantibodies in autoimmune diseases: Clinical and critical evaluation. Kapsogeorgou EK, Tzioufas AG. *Isr Med Assoc J.* 2016 Sep;18(9):519-524.

429. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. Suurmond J, Diamond B. J *Clin Invest.* 2015 Jun;125(6):2194-202.

430. Discovery of 2 Distinctive Lineages of Lymphocytes, T Cells and B Cells, as the Basis of the Adaptive Immune System and Immunologic Function: 2019 Albert Lasker Basic Medical Research Award. Cooper MD, Miller JFAP. *JAMA.* 2019 Oct;322(13):1247-48.

431. Antibody responses in COVID-19: A review. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, et al. *Front Immunol.* 2021;12:633184.

432. Antibody tests for identification of current and past infection with SARS CoV-2. Deeks JJ, Dinnes J, Takwoingi Y, et al. *Cochrane Database Syst Rev.* 2020;6(6):CD013652.

433. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Lai CC, Wang JH, Hsueh PR. *J Infect Dis.* 2020;101:314-22.

434. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Robbiani DF, Gaebler C, Muecksch F, et al. *Nature.* 2020;584(7821):437–42.

435. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Seow J, Graham C, Merrick B, et al. *Nat Microbiol.* 2020;5(12):1598-1607.

436. Kinetics of viral load and antibody response in relation to COVID-19 severity. Wang Y, Zhang L, Sang L, et al. *J Clin Invest.* 2020;130(10):5235–44.

437. Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection. Orth-Höller D, Eigentler A, Weseslindtner L, Möst J. *Emerg Microbes Infect.* 2020;9(1):1–12.

438. Humoral Immune Response to SARS-CoV-2 in Iceland. Gudbjartsson DF, Norddahl GL, Melsted P, et al. *NEJM.* 2020;383(18):1724-34.

439. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Wajnberg A, Amanat F, Firpo A, et al. 2020;370(6521):1227-30.

440. Antibody tests have higher sensitivity at 15 days after symptom onset and 99% specificity for detecting SARS-CoV-2. Lawandi A, Danner RL. *Intern Med.* 2020;173(10):JC57.

441. Evolution of antibody immunity to SARS-CoV-2. Gaebler C, Wang Z, Lorenzi JCC, et al. *Nature.* 2021;591(7851): 639-44.

442. Predictors of nonseroconversion after SARS-CoV-2 infection. Liu W, Russell RM, Bibollet-Ruche F, et al. *Emerg Infect Dis.* 2021;27(9):2454-2458.

443. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. Oved K, Olmer L, Shemer-Avni Y, et al. *EClinicalMedicine* 2020; 29:100651.

444. SARS-CoV-2 seroconversion and viral clearance in patients hospitalized with COVID-19: Viral load predicts antibody response. Masia M, Telenti G, Fernandez M, et al. *Open Forum Infect Dis.* 2021;8(2):ofab005.

445. Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study. Thiruvengadam R, Chattopadhyay S, Mehdi F, et al. *Am J Trop Med Hyg.* 2021;105(1):66-72.

446. SARS-CoV-2 seroconversion and viral clearance in patients hospitalized with COVID-19: Viral load predicts antibody response. Masia M, Telenti G, Fernandez M, et al. *Open Forum Infect Dis.* 2021:8(2):ofab005.

447. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. Wellinghausen N, Plonné D, Voss M, et al. *J Clin Virol.* 2020;130:104542.

448. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. Joyner MJ, Carter RE, Senefeld JW, et al. *NEJM.* 2021;384(11):1–13.

449. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Rijkers G, Murk JL, Wintermans B, van Looy B, et al. *J Infect Dis.* 2020;222(8):1265–9.

450. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. *PLoS One.* 2020;15(10):e0240502.

451. Quantifying antibody kinetics and RNA detection during early-phase SARSCoV-2 infection by time since symptom onset. Borremans B, Gamble A, Prager KC, et al. *Elife.* 2020;9:1–27.

452. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. *Nat Commun.* 2020;11(1):1–16.

453. Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and Association with Disease Severity. Luo YR, Chakraborty I, Yun C, et al. *Clin Infect Dis.* 2021;73(9):e3095-97.

454. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Ren L, Zhang L, Chang D, et al. *Commun Biol.* 2020;3(1):1–7.

455. A longitudinal study of SARS-CoV-2 infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Legros V, Denolly S, Vogrig M, et al. *Cell Mol Immunol.* 2021;18(2):318-27.

456. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: A retrospective study. Guo L, Wang Y, Kang L, Hu Y, et al. *Emerg Microbes Infect.* 2021;10(1):664-76.

457. Humoral immune responses and neutralizing antibodies against SARS-CoV-2: Implications in pathogenesis and protective immunity. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, et al. *Biochem Biophys Res Commun.* 2021;538:187-91.

458. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Lucas C, Klein J, Sundaram ME, et al. *Nat Med.* 2021;27(7):1178-86.

459. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Legros V, Denolly S, Vogrig M, et al. *Cell Mol Immunol.* 2021;18(2):318-27.

460. SARS-CoV-2 Infection severity is linked to superior humoral immunity against the spike. Guthmiller JJ, Stovicek O, Wang J, et al. *mBio.* 2021;12(1):e02940-20.

461. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Lynch KL, Whitman JD, Lacanienta NP, et al. *Clin Infect Dis.* 2021;72(2):301-08.

462. The dynamics of immune response in COVID-19 patients with different illness severity. Zhang B, Yue D, Wang Y, et al. *J Med Virol.* 2020 July:1–8.

463. The kinetics of viral load and antibodies to SARS-CoV-2. Sun J, Tang X, Bai R, et al. Clin Microbiol Infect. 2020;26(12):1–16.

464. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Chen X, Pan Z, Yue S, et al. *Signal Transduct Target Ther.* 2020;5(1):1–6.

465. Antibody Responses in COVID-19: A Review. Chvatal-Medina M, Mendez-Cortina Y, Pablo J, Patiño PJ, et al. *Front Immunol.* 2021;12:633184.

466. High neutralizing antibody titer in intensive care unit patients with COVID-19. Liu L, To KKW, Chan KH, et al. *Emerg Microbes Infect.* 2020;9(1):1–30.

467. Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Terpos E, Politou M, Sergentanis TN, et al. Microorganisms. 2020;8(12):1885.

468. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. Klein SL, Pekosz A, Park HS, et al. *J Clin Invest.* 2020;130(11):6141–50.

469. Postconvalescent SARS-CoV-2 IgG and neutralizing antibodies are elevated in individuals with poor metabolic health. Racine-Brzostek SE, Yang HS, Jack GA, et al. *J Clin Endocrinol Metab.* 2021;106(5):e2025-e2034.

470. Diverse functional autoantibodies in patients with COVID-19. Wang EY, Mao T, Klein J, et al. *medRxiv.* 2021 Feb:2020.12.10.20247205.

471. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Chang SE, Feng A, Meng W, et al. *Nat Commun.* 2021 Sep;12(1):5417.

472. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Bastard P, Gervais A, Le Voyer T, et al. *Sci Immunol.* 2021;6(62):eabl4340.

473. Pre-existing autoantibodies neutralizing high concentrations of type I Interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. Solanich X, Rigo-Bonnin R, Gumucio VD, et al. *J Clin Immunol.* 2021 Nov;41(8):1733-44.

474. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. Liu Y, Ebinger JE, Mostafa R, et al. *J Transl Med.* 2021 Dec;19(1):524.

475. Positive anti-SSA/Ro antibody in a woman with SARS-CoV-2 infection using immunophenotyping: A case report. Huang PI, Lin TC, Liu FC, et al. *Medicina (Kaunas).* 2020;56(10):521.

476. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: A case-based review: High levels of anti-SSA/Ro antibodies in COVID-19. Fujii H, Tsuji T, Yuba T, Tanaka S, et al. *Clin Rheumatol.* 2020;39(11):3171-75.

477. Diverse functional autoantibodies in patients with COVID-19. Wang EY, Mao T, Klein J, et al. *medRxiv.* 2021;2020.12.10.20247205.

478. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Zuo Y, Estes SK, Ali RA, et al. *Sci Transl Med.* 2020;12(570)eabd3876.

479. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Bastard P, Rosen LB, Zhang Q, et al. *Science.* 2020;370(6515):eabd4585.

480. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection: Future roadmap for laboratory diagnosis. Peker BO, Şener AG, Kaptan Aydoğmuş F. *J Immunol Methods.* 2021;499:113174.

481. Water structure and interactions with protein surfaces. Raschke TM. *Curr Opin Struct Biol.* 2006 Apr;16(2):152-9.

482. Water Determines the Structure and Dynamics of Proteins. Bellissent-Funel MC, Hassanali A, Havenith M, Henchman R, Pohl P, Sterpone F, van der Spoel D, Xu Y, Garcia AE. *Chem Rev.* 2016 Jul 13;116(13):7673-97.

483. Water mediation in protein folding and molecular recognition. Levy Y, Onuchic JN. *Annu Rev Biophys Biomol Struct.* 2006;35:389-415.

484. Dynamics of hydration water in proteins. Teixeira J. *Gen Physiol Biophys.* 2009;28(2):168-73.

485. Sub-terahertz spectroscopy reveals that proteins influence the properties of water at greater distances than previously detected. Sushko O, Dubrovka R, Donnan RS. *J Chem Phys.* 2015 Feb 7;142(5):055101.

486. *Species and Specificity: An Interpretation of the History of Immunology.* Pauline M H Mazumdar. Cambridge University Press. 1995.

487. Natural autoantibodies in the physiology and pathophysiology of the immune system. Avrameas S, Selmi C. *J Autoimmun.* 2013;41:46–49.

488. The emerging concept of pathogenic natural autoantibodies. George J, Gilburd B, Shoenfeld Y. *Hum Antibodies.* 1997;8(2):70-75.

489. Naturally occurring auto-antibodies in homeostasis and disease. Lutz HU, Binder CJ, Kaveri S. *Trends Immunol.* 2009 Jan;30(1):43-51.

490. Homeostatic roles of naturally occurring antibodies: An overview. Lutz HU. *J Autoimmun.* 2007 Dec;29(4):287-94.

491. Systemic autoinflammatory diseases. Krainer J, Siebenhandl S, Weinhäusel A. *J Autoimmun.* 2020 May;109;102421.

492. Autoinflammatory diseases: State of the art. Georgin-Lavialle S, Fayand A, Rodrigues F, et al. *Presse Med.* 2019 Feb;48(1 Pt2):e25-48.

493. New insights on multigenic autoinflammatory diseases. Efthimiou P, Petryna O, Nakasato P, et al. *Ther Adv Musculoskelet Dis.* 2022 Sep;14:1759720X221117880.

494. The expanding spectrum of autoinflammatory diseases. Migita K, Fujita Y, Asano T, et al. *Intern Med.* 2022 Mar 19.

495. Autoinflammatory diseases. Rubartelli A. *Immunol Lett.* 2014 Oct;161(2):226-30.

496. Autoinflammatory conditions: When to suspect? How to treat? Grateau G, Duruöz MT. *Best Pract Res Clin Rheumatol.* 2010 Jun;24(3):401-11.

497. Development of the spleen. Jones JF. *Lymphology.* 1983 Jun;16(2):83-9.

498. Development and function of the mammalian spleen. Brendolan A, Rosado MM, Carsetti R, et al. *Bioessays.* 2007 Feb;29(2):166-77.

499. *Blood, Pure and Eloquent.* Maxwell M Wintrobe. McGraw-Hill Book Company. 1980.

500. Post-splenectomy sepsis: A review of the literature. Tahir F, Ahmed J, Malik F. *Cureus.* 2020 Feb;12(2):e6898.

501. Overwhelming post-splenectomy infection (OPSI): A case report and review of the literature. Tomich EB. *J Emerg Med.* 2012 Oct;43(4):758-63.

502. Overwhelming post-splenectomy infection syndrome: Variability in timing with similar presentation. *Cureus.* 2020 Aug;12(8):e9914.

503. Hyposplenism: A comprehensive review. Part I: basic concepts and causes. William BM, Corazza GR. *Hematology.* 2007 Feb;12(1):1-13.

504. Hyposplenism: A comprehensive review. Part II: clinical manifestations, diagnosis, and management. William BM, Thawani N, Sae-Tia S, et al. *Hematology.* 2007 Apr;12(2):89-98.

505. From sadness to stiffness: The spleen's progress. Riva MA, Ferraina F, Paleari A, et al. *Intern Emerg Med.* 2019 Aug;14(5):739-43.

506. Functional hyposplenism. Kirkineska L, Perifanis V, Vasiliadis T. *Hippokratia.* 2014 Jan;18(1):7-11.

507. Asplenia and spleen hypofunction. Lenti MV, Luu S, Carsetti R, et al. *Nat Rev Dis Primers.* 2022 Nov;8(1):71.

508. Hyposplenism in systemic lupus erythematosus. Neilan BA, Berney SN. *J Rheumatol.* 1983;10(2):332-34.

509. Reticuloendothelial function in rheumatoid arthritis: Correlation with disease activity and circulating immune complexes. Henderson JM, Bell DA, Harth M, et al. *J Rheumatol.* 1981 May;8(3):486-89.

510. Splenic phagocytic function in patients with inflammatory bowel disease. Jewell DP, Berney JJ, Pettit JE. *Pathology.* 1981 Oct;13(4):717-23.

511. Hyposplenism in inflammatory bowel disease. Ryan FP, Smart RC, Holdsworth CD, et al. *Gut.* 1978 Jan;19(1):50-55.

512. Reticuloendothelial function in coeliac disease and ulcerative colitis. Palmer KR, Barber DC, Sherriff SB, et al. *Gut.* 1983 May;24(5):384-88.

513. Immunological abnormalities in splenic atrophy. Wardrop CA, Dagg JH, Lee FD, et al. *Lancet.* 1975 Jul;297923):4-7.

514. [Diagnostic value of radionuclide visualization of the reticuloendothelial system of macrophages in multiple sclerosis]. El'chaninov AP, Artiushkin AV, Skoromets AA. *Zh Nevropatol Psikhiatr Im S S Korsakova.* 1986:86(2):200-03.

515. Sjögren's syndrome and acquired splenic atrophy with septic shock: A case report. Santos N, Silva R, Rodrigues J, et al. *J Med Case Rep.* 2014 Jan;8:10.

516. Hyposplenism, Hashimoto's Autoimmune Thyroiditis and Overlap Syndrome (Celiac Disease and Autoimmune Hepatitis Type 1). Balaceanu A, Omer S, Stirban R, et al. *Am J Med Sci.* 2020 Sep;360(3):293-99.

517. Potential role of Howell-Jolly bodies in underlying functional hyposplenism: A prospective single-institute study. Nakagami Y, Uchino K, Okada H, et al. *Int J Hematol.* 2020 Oct;112(4):544-52.

518. *Galen's Theory of Black Bile.* Keith Andrew Stewart. Publ Brill. 2019.

519. *Galen's System of Physiology and Medicine.* Rudolph E. Siegel. Publ S. Karger (Basel). 1968.

520. Functions of lysosomes. De Duve C, Wattiaux R. *Annu Rev Physiol.* 1966;28:435-492.

521. The lysosome turns fifty. De Duve C. *Nat Cell Biol.* 2005;7:847-849.

522. Historical landmarks of autophagy research. Ohsumi Y. Cell Res. 2014 Jan;24(1):9-23.

523. Autophagy mediates neutrophil responses to bacterial infection. Chargui A, El May MV. *APMIS.* 2014 Nov;122(11):1047-58.

524. Autophagy in innate immunity against intracellular bacteria. Amano A, Nakagawa I, Yoshimori T. *J Biochem.* 2006 Aug;140(2):161-6.

525. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Deretic V. *Immunol Rev.* 2011 Mar;240(1):92-104.

526. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. Frank MM, Hamburger MI, Lawley TJ, et al. *N Engl J Med.* 1979;300:518-523.

527. Defective reticuloendothelial system function in rheumatoid arthritis. Williams BD, Pussell BA, Lockwood CM, et al. *Lancet.* 1979 Jun;1(8130): 1311-1314.

528. Reticuloendothelial function in rheumatoid arthritis: Correlation with disease activity and circulating immune complexes. Henderson JM, Bell DA, Harth M, et al. *J Rheumatol.* 1981 May;8(3):486-89.

529. Sjögren's syndrome: A defect in reticuloendothelial system F_C-receptor-specific clearance. Hamburger MI, Moutsopoulos HM, Lawley TJ, et al. *Ann Intern Med.* 1979 Oct;91(4):534-38.

530. Reticuloendothelial F$_C$ receptor function in patients with Sjögren's syndrome. O'Sullivan MM, Walker DM, Williams BD. *Clin Exp Immunol.* 1985 Sep;61(3):483-88.

531. Circulating immune complexes (CIC) in connective tissue diseases (CTD). Scheiber L, Maini RN. *Neth J Med.* 1984;27(9):327-39.

532. Association of Sjögren's syndrome with C4 deficiency, defective reticuloendothelial function and circulating immune complexes. Hersey P, Lawrence S, Prendergast D, et al. *Clin Exp Immunol.* 1983 Jun;52(3):551-60.

533. Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus. Witte T, Dumoulin FL, Gessner JE, et al. *J Clin Invest.* 1993 Sept;92(3):1181-87.

534. Immune complex clearance by complement receptor type 1 in SLE. Kavai M. *Autoimmun Rev.* 2008 Dec;8(2):160-64.

535. The role of defective clearance of apoptotic cells in systemic autoimmunity. Muñoz LE, Lauber K, Schiller M. *Nat Rev Rheumatol.* 2010 May;6(5):280-89.

536. Clearance deficiency and cell death pathways: A model for the pathogenesis of SLE. Mahajan A, Herrmann M, Muñoz LE. *Front Immunol.* 2016 Feb;7:35.

537. Autoimmunity and chronic inflammation: Two clearance-related steps in the etiopathogenesis of SLE. Muñoz LE, Janko C, Schulze C, et al. *Autoimmun Rev.* 2010 Nov;10(1):38-42.

538. The role of incomplete clearance of apoptotic cells in the etiology and pathogenesis of SLE. Muñoz LE, Lauber K, Schiller M, et al. *Z Rheumatol.* 2010 Mar;69(2):152.

539. Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease. Wang EJ, Wu MY, Ren ZY, et al. *Burns Trauma.* 2023 May;11:tkad004.

540. The role of defective clearance of apoptotic cells in systemic autoimmunity. *Nat Rev Rheumatol.* 2010 May;6(5):280-89.

541. Inflammatory etiopathogenesis of systemic lupus erythematosus: An update. Podolska MJ, Biermann MH, Maueröder C, et al. *J Inflamm Res.* 2015 Aug;8:161-71.

542. Clearance deficiency and cell death pathways: A model for the pathogenesis of SLE. Mahajan A, Herrmann M, Muñoz LE. *Front Immunol.* 2016 Feb;7:35.

543. Autoimmunity and chronic inflammation: Two clearance-related steps in the etiopathogenesis of SLE. Muñoz LE, Janko C, Schulze C, et al. *Autoimmun Rev.* 2010 Nov;10(1):38-42.

544. Immune complexes and reticuloendothelial function in human disease. Lawley TJ. *J Invest Dermatol.* 1980 May;74(5):339-43.

545. Reticuloendothelial F$_C$ receptor function in SLE patients. I. Primary HLA linked defect or acquired dysfunction secondary to disease activity? van der Woude FJ, nan der Glessen M, Kallenberg CG, et al. *Clin Exp Immunol.* 1984 Mar;55(3):473-80.

546. Splenic reticuloendothelial function in patients with active rheumatoid arthritis. Gordon PA, Davis P, Russell AS, et al. *J Rheumatol.* 1981 May;8(3):490-93.

547. Defective reticuloendothelial system C3b mediated clearance in rheumatoid arthritis and vasculitis. Cunningham TJ, Nicholls KM, Chen SL, et al. *J Rheumatol.* 1985 Aug;12(4):675-79.

548. Splenic phagocytic function in patients with inflammatory bowel disease. Jewell DP, Berney JJ, Pettit JE. *Pathology.* 1981 Oct;13(4):717-23.

549. Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Lee KH, Kronbichler A, Park DD, et al. *Autoimmune Rev.* 2017 Nov;16(11):1160-73.

550. Neutrophil extracellular traps in immunity and disease. Papayannopoulos V. *Nat Rev Immunol.* 2018 Feb;18(2):134-47.

551. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Wigerblad G, Kaplan MJ. *Nat Rev Immunol.* 2023 May;23(5):274-88.

552. Neutrophil extracellular traps and their implications in cardiovascular and inflammatory disease. Klopf J, Brostjan C, Eilenberg W. *Int J Mol Sci.* 2021 Jan;22(2):559.

553. Neutrophil extracellular traps take center stage in driving autoimmune responses. Fousert E, Toes R, Desai J. *Cells.* 2020 Apr;9(4):915.

554. An emerging role for neutrophil extracellular traps in noninfectious disease. Fousert E, Toes R, Desai J. *Nat Med.* 2017 Mar;23(3):279-87.

555. Neutrophil extracellular traps in COVID-19. Zuo Y, Yalavarthi S, Shi H, et al. *JCI Insight.* 2020 Jun;5(11):e138999.

556. NETosis and neutrophil extracellular traps in COVID-19: Immunothrombosis and beyond. Zhu Y, Chen X, Liu X. *Front Immunol.* 2022 Mar;13:838011.

557. Autophagy dysfunction in autoinflammatory diseases. Hua Y, Shen M, McDonald C, Yao Q. *J Autoimmun.* 2018 Mar;88:11-20.

558. Autophagy and the immune response. Cui B, Lin H, Yu J, et al. *Adv Exp Med Biol.* 2019;1206:595-634.

559. Autophagy in infection, inflammation and immunity. Deretic V, Saitoh T, Akira S. *Nat Rev Immunol.* 2013 Oct;13(10):722-37.

560. Autophagy in autoimmune disease. Yang Z, Goronzy JJ, Weyand CM. *J Mol Biol (Berl).* 93(7):707-17.

561. Autophagy in inflammation, infection, and immunometabolism. Deretic V. *Immunity.* 54(3):437-53.

562. Autophagy balances inflammation in innate immunity. Deretic V, Levine B. *Autophagy.* 2018;14(2):243-51.

563. Regulation of inflammasomes by autophagy. Saitoh T, Akira S. *J Allergy Clin Immunol.* 2016 Jul;138(1):28-36.

564. Autophagy in rheumatic diseases: Role in the pathogenesis and therapeutic approaches. Celia AI, Colafrancesco S, Barbati C, et al. *Cells.* 2022 Apr;11(8):1359.

565. Role of autophagy in the pathogenesis of multiple sclerosis. Liang P, Le W. *Neurosci Bull.* 2015 Aug;31(4):435-44.

566. Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Hsu HC, Chen YH, Lin TS, et al. *Biochim Biophys Acta Mol Basis Dis.* 2021 Feb;1867(2):166027.

567. Autophagy in Crohn's disease: Converging on dysfunctional innate immunity. Alula KM, Theiss AL. *Cells.* 2023 Jul;12(13):1779.

568. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Zanatta E, Colombo C, D'Amico G, et al. *Int J Mol Sci.* 2019 Nov;20(22):5563.

569. Coronary microvascular disease: the 'meeting point' of cardiology, rheumatology, and endocrinology. Markousis-Mavrogenis G, Bacopoulou F, Mavragani C, et al. *J Clin Invest.* 2022 May;52(5):e13737.

570. Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. Faccini A, Kaski JC, Camici PG. *Eur Heart J.* 2016 Jun;37(23):1799-1806.

571. The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions. Konst RE, Guzik TJ, Kaski JC, et al. *Cardiovasc Res.* 2020 Mar;116(4):817-28.

572. Insights into the role of mitochondrial ion channels in inflammatory responses. Ponnalagu D, Singh H. *Front Physiol.* 2020 Apr;11:258.

573. Mitochondria: sovereign of inflammation? *Eur J Immunol.* 2011 May;41(5):1196-1202.

574. Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics. Mishra SR, Mahapatra KK, Behera BP, et al. *J Biochem Cell Biol.* 2021 Jul;136:106013.

575. Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. Biczo G, Vegh ET, Shalbueva N, et al. *Gastroenterology.* 2018 Feb;154(3):689-703.

576. Mitochondria in autoinflammation: cause, mediator or bystander? van der Burgh R, Boes M. *Trends Endocrinol Metab.* 2015 May;26(5):263-71.

577. A role for mitochondria in NLRP3 activation. Zhou R, Yazdi AS, Menu P, et al. *Nature.* 2011 Jan;469(7329):221-25.

578. Lysosomal potassium channels. Wu Y, Xu M, Wang P, et al. *Cell Calcium.* 2022 Mar;102:102536.

579. The role of lysosomal ion channels in lysosome dysfunction. Kendall RL, Holian A. *Inhal Toxicol.* 2021 Feb;33(2):41-54.

580. Ion channels and transporters in autophagy. Zhang R, Kang R, Klionsky DJ, et al. *Autophagy.* 2022 Jan;18(1):4-23.

581. Mitochondria-lysosome contacts regulate mitochondrial Ca^{2+} dynamics via lysosomal TRPML1. Peng W, Wong YC, Krainc D. *Proc Natl Acad Sci USA.* 2020 Aug;117(32):19266-275.

582. Regulation of lysosomal ion homeostasis by channels and transporters. Xiong J, Zhu MX. *Sci China Life Sci.* 2016 Aug;59(8):777-91.

583. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Liu K, Zhao E, Ilyas G, et al. *Autophagy.* 2015;11(2):271-84.

584. Interactions of autophagy of autophagy and the immune system in health and disease. Pant A, Yao X, Lavedrine A, et al. *Autophagy Rep.* 2022;1(1):438-515.

585. Deficient chaperone-mediated autophagy promotes inflammation and atherosclerosis. Qiao L, Ma J, Zhang Z, et al. *Circ Res.* 2021 Dec;129(12):1141-57.

586. Via a regulation system "spleen-liver" for the oxidative metabolism of the body tissues and especially the heart. Rein H. *Nat Sci.* 1949;36:260–268 (in German).

587. The role of the spleen and liver in coronary or hypoxic myocardial insufficiency. Rein H, Dohrn A. *Pflugers Arch Gesamte Physiol Menschen Tiere.* 1951;253:435–458 (in German).

588. A transient decrease in spleen size following stroke corresponds to splenocyte release into the systemic circulation. Seifert HA, Hall AA, Chapman CB, et al. *J Neuroimmune Pharmacol.* 2012 Dec;7(4):1017-24.

589. Splenic size as an indicator of hemodynamics and prognosis in patients with heart failure. Hiraiwa H, Okumura T, Sawamura A, et al. *Heart Vessels.* 2022 Aug;37(8):1344-55.

590. The cardiosplenic axis: another obscure pathophysiological function of the spleen and its investigation using molecular imaging. Dunford A, Keramida G, Anagnostopoulos CD, et al. *Nuc Med Commun.* 2017 Mar;38(3):205-08.

591. Splenic metabolic activity predicts risk of future cardiovascular events: Demonstration of a cardiosplenic axis in humans. Emami H, Singh P, MacNabb M, et al. *JACC Cardiovasc Imaging.* 2015 Feb;8(2):121-30.

592. Spleen contraction during sudden eupneic hypoxia elevates hemoglobin concentration. Pernett F, Schagatay F, Vildevi C, et al. *Front Physiol.* 2021 Sep;12:729123.

593. The human spleen during physiological stress. Stewart IB, McKenzie DC. *Sports Med.* 2002;32(6):361-69.

594. Responses of the human spleen to exercise. Shephard RJ. *Sports Sci.* 2016;34(10):929-36.

595. Normal structure, function, and histology of the spleen. Cesta MF. *Toxicol Pathol.* 2006;34(5):455-65.

596. Splenic size as an indicator of hemodynamics and prognosis in patients with heart failure. Hiraiwa H, Okumura T, Sawamura A, et al. *Heart Vessels.* 2022 Aug;37(8):1344-55.

597. Splenic contraction: a new member of the hypovolemic shock complex. Enslow MS, Preece SR, Wildman-Tobriner B, et al. *Abdom Radiol (NY).* 2018 Sep;43(9):2375-83.

598. Relationship between splenic size and splenic function. Smart RC, Ryan FP, Holdworth CD, et al. *Gut.* 1978 Jan;19(1):56-59.

599. Enhanced splenic volume and contraction in elite endurance athletes. Holmström PK, Karlsson Ö, Lindblom H, et al. *J Appl Physiol.* 2021 Aug;131(2):474-86.

600. Spleen contraction elevates hemoglobin concentration at high altitude during rest and exercise. Schagatay E, Lunde A, Nilsson S, et al. *Eur J Appl Physiol.* 2020 Dec;120(12);2693-2704.

601. Splenic contraction is enhanced by exercise at simulated high altitude. Lodin-Sundström A, Holmström P, Ekstam M, et al. *Eur J Appl Physiol.* 2021 Jun;121(6):1725-32.

602. The effects of high altitude ascent on splenic contraction and the diving response during voluntary apnoea. Holmström PK, Bird JD, Thrall SF, et al. *Exp Physiol.* 2021 Jan;106(1):160-74.

603. Ozone preconditioning: Waking up the dragon. Thorp KE, Thorp JA. *G Med Sci.* 2021;2(3):10-39.

604. Energy dynamics in chronic heart failure, chronic kidney disease & the cardiorenal syndrome: A new causal paradigm. Thorp KE, Thorp JA, Northrup C, et al. *G Med Sci.* 2023;4(1):290-347.

605. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Swirski FK, Nahrendorf M, Etzrodt M, et al. *Science.* 2009 Jul;325(5940):612–16.

606. Anatomy of a discovery: M1 and M2 macrophages. Mills CD. *Front Immunol.* 2015 May;6:212.

607. M1 and M2 macrophages: the chicken and the egg of immunity. Mills CD, Ley K. *J Innate Immun.* 2014;6(6):716-26.

608. M1 and M2 Macrophages: Oracles of Health and Disease. Mills CD. *Crit Rev Immunol.* 2012;32(6):463-88.

609. The role of innate immune cells in cardiac injury and repair: A metabolic perspective. Banerjee D, Tian R, Cai S. *Curr Cardiol Rep.* 2023 Jul;25(7):631-40.

610. Splenic leukocytes define the resolution of inflammation in heart failure. Halade GV, Norris PC, Kain V, et al. *Sci Signal.* 2018 Mar;11(520):eaao1818.

611. Immunometabolism of phagocytes and relationships to cardiac repair. Zhang S, Bories G, Lantz C, et al. *Front Cardiovasc Med.* 2019 Apr;6:42.

612. The evolving roles of cardiac macrophages in homeostasis, regeneration, and repair. Alvarez-Argote S, O'Meara CC. *Int J Mol Sci.* 2021 Jul;22(15):7923.

613. Transition of macrophages to fibroblast-like cells in healing myocardial infarction. Haider N, Boscá L, Zandbergen HR, et al. *J Am Coll Cardiol.* 2019 Dec;74(25):3124-35.

614. Splenic metabolic activity predicts risk of future cardiovascular events: Demonstration of a cardiosplenic axis in humans. Emami H, Singh P, MacNabb M, et al. *JACC Cardiovasc Imaging.* 2015 Feb;8(2):121-30.

615. Mitochondrial function in macrophages controls cardiac repair after myocardial infarction. Weissman D, Maack C. *J Clin Invest.* 2023 Feb;133(4):e167079.

616. Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. Cai S, Zhao M, Zhou B, et al. *J Clin Invest.* 2023 Feb;133(4):e159498.

617. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Balk RA. *Virulence.* 2014 Jan;5(1):20-26.

618. The systemic inflammatory response syndrome. Robertson CM, Coopersmith CM. *Microbes Infect.* 2006 Apr;8(5):1382-89.

619. Systemic inflammatory response syndrome. Botwinsky CA. *Neonatal Netw.* 2001 Aug;20(5):21-8.

620. Remodeling of the mononuclear phagocytic network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Ismahil MA, Hamid T, Bansal SS, et al. *Circ Res.* 2014 Jan;114(2):266-82.

621. The cardiosplenic axis is essential for the pathogenesis of ischemic heart failure. Prabhu SD. *Trans Am Clin Climatol Assoc.* 2018;129:202-214.